SEFE (SEFE) Begins Construction of Electroplating Laboratory

SEFE, Inc. (OTCBB/OTCQB: SEFE) (the “Company”), a solutions-driven company developing products and technologies that improve worldwide access to basic resources, including energy, food and water, today announces the beginning of construction of an in-house electroplating/polishing facility at its headquarters in Boulder, Colorado. The facility will be used to support iterative testing of various corona discharge air terminal configurations.

The plating laboratory will support the application of protective coatings to air terminals to reduce oxidation and corrosive effects. In addition, the team will use electropolishing techniques to do process development on air terminal corona emitters. The iterative prototyping approach will be used in conjunction with the Faraday cage facility to rapidly build and test different corona emitter configurations.

“Our plating laboratory will be used to support our air terminal development program on an ongoing basis,” stated SEFE Director of Engineering Michael Hurowitz. “After careful analysis our team has determined pursuing this process development in-house will save significant R&D capital.”

About SEFE, Inc.

SEFE focuses on pushing the boundaries of what’s possible, embracing innovation and employing the cutting-edge to solve problems, and offering sustainable solutions to a world hungry for invention, direction and leadership. SEFE is technology- and solutions-driven, focusing on developing inventions that provide a real-world impact and true profitability. So, success is measured by both a sustainable return on investment, as well as a project’s sustainability from an environmental perspective.

For more information, visit www.SEFElectric.com.

Forward-Looking Statements

This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements regarding our expected future financial position, results of operations, cash flows, financing plans, business strategy, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, as well as statements that include words such as “anticipate,” “if,” “believe,” “plan,” “estimate,” “expect,” “intend,” “may,” “could,” “should,” “will,” and other similar expressions are forward-looking statements. All forward-looking statements involve risks, uncertainties and contingencies, many of which are beyond our control, which may cause actual results, performance, or achievements to differ materially from anticipated results, performance, or achievements. We are under no obligation to (and expressly disclaim any such obligation to) update or alter our forward-looking statements, whether as a result of new information, future events or otherwise.

RF Industries’ (RFIL) Third Quarter Sales Increase 51% to a Record $7,472,000

RF INDUSTRIES, LTD. (NASDAQ:RFIL) today announced record quarterly sales and consolidated net income for the third quarter ended July 31, 2012. Net sales increased 51% to a quarterly record $7,472,000 compared to $4,948,000 in the same quarter last year. Consolidated net income was a quarterly record $735,000, or $0.10 per diluted share, compared to consolidated net income of $65,000, or $0.01 per diluted share in the same quarter last year. Consolidated net income for the third quarter last year was affected by non-recurring expenses of approximately $562,000 associated with the acquisition of Cables Unlimited and certain stockholder issues and activities.

RFI also announced that its Board declared a regular quarterly cash dividend of $0.05 per common share, payable October 15, 2012 to shareholders of record on September 30, 2012.

Third Quarter Review

“Our focus in the acquisition of Cables Unlimited (CU) in June 2011 was to capitalize on RFI’s strong product distribution to the wireless industry. Working closely with our distributors, Cables Unlimited designed and introduced the new OptiFlex™ power and fiber optic cabling system for high-speed wireless antenna towers. Multiple larger orders for OptiFlex supports our strategy of leveraging RFI’s wireless product line by incorporating fiber optic and power components.

“Total operating profits increased to $1,094,000 compared to breakeven in the same period last year. We anticipate that strong performance from all business segments should lead to record sales in the fourth quarter ending October 31, 2012,” said Howard Hill, RFI’s CEO.

RF Connector and Cable Assembly segment sales increased 18% to a record $3,871,000 compared to $3,274,000 in the same quarter last year. Operating income for this segment was $669,000, compared to an operating loss of $99,000 in the same period last year. The segment’s loss in the third quarter last year was due to the total of $562,000 in non-recurring acquisition related and other expenses, as discussed above.

Cables Unlimited’s third quarter sales were a record $2,728,000, compared to sales of $909,000 for the 46 day period after its acquisition on June 15, 2011 last year. Gross margin was 35% compared to 37% of sales in the same quarter last year, while operating profitability significantly improved to $446,000, or 16% of sales, compared to $97,000, or 11% of sales in the same quarter last year.

“During the third quarter, CU announced receipt of orders totaling $1,400,000 for its newly designed OptiFlex™ Hybrid Custom Fiber Optic & DC Power Cabling solution and shipped a significant portion of these orders during the quarter. We are extremely encouraged by the subsequent receipt of additional similar-sized orders for this new product,” said Hill.

Bioconnect sales increased 12% to a third quarter record $570,000 compared to $510,000 in the same period last year. Gross margin declined to 39% from 41% of sales due to higher raw materials costs. Operating income declined slightly to $116,000 compared to $121,000 in the same quarter last year as Bioconnect increased hiring and invested in the development of new products for the coming year.

RF Wireless sales increased 19% to $304,000 from $255,000 in the same quarter last year. A change in product mix, combined with customer requested rescheduling of RadioMobile product shipments to a public service organization lowered segment gross margin to 26% compared to 39% of sales in the same quarter last year. The operating loss for this segment was $138,000 compared to $118,000 in the same quarter last year.

“RadioMobile’s product shipments associated with its $2,600,000 contract with the Los Angeles County Fire Department have been rescheduled for delivery in the current fourth quarter and remainder of calendar 2012. We anticipate significant improvement in RF Wireless sales and profitability in the next two quarters,” said Hill.

As of July 31, 2012, RFI reported cash and cash equivalents of $5,630,000, working capital of $13,719,000, a current ratio of 6 to 1, no long-term debt and stockholders’ equity of $19,094,000, or $2.77 per outstanding share.

Nine Months Review

For the nine months ended July 31, 2012, sales increased 46% to $19,703,000 compared to $13,479,000 in the same period last year. Gross margin for the first nine months of fiscal 2012 declined to 45% compared to 51% of sales, primarily due to higher sales of lower-margin products at Cables Unlimited. Consolidated net income increased 77% to $1,455,000, or $0.19 per diluted share, compared to $823,000, or $0.12 per diluted share, in the same period last year.

For the nine month period RF Connector and Cable Assembly segment sales increased 2% to $10,391,000 from $10,144,000 in the same period last year, led by a 6% increase in sales at the RF Connector division. Segment gross margin was 52% compared to 54% in the same period last year. Operating income for this segment was $1,155,000 compared to $1,136,000 for the first nine months of fiscal 2011.

Sales at Cables Unlimited were $6,008,000 for the first nine months of fiscal 2012, compared to sales of $909,000 in the 46 day period after CU’s acquisition on June 15, 2011. Gross margin was 34% compared to 37% of sales for the comparable periods. Operating income was $648,000, or 11% of sales for the nine month period, compared to $97,000, or 11% of sales in the same period last year.

Bioconnect sales increased 11% to $2,012,000 for the nine month period, compared to $1,809,000 in the same period last year, helping to raise gross margin to 42% from 39% of sales in the same period last year. Higher gross margin and lower selling and general expenses, as a percent of sales, increased operating income 30% to $556,000 compared to $427,000 for the same period last year.

RF Wireless segment sales increased 109% to $1,293,000, compared to $617,000 in the same period last year. Gross margin for both periods was 42%. Higher sales and reduced selling and general expenses improved operating profits by $366,000, resulting in a nine month operating loss of $143,000 compared to an operating loss of $509,000 for the same period of fiscal 2011.

For fiscal 2012 to date, under the Company’s previously announced stock repurchase program, RFI has repurchased 324,871 common shares in open market or private transactions.

Third Quarter Conference Call

RFI has scheduled a conference call this morning, Monday, September 10, 2012, at 12:00 p.m. EDT to discuss its results for the quarter. The dial in number is 800-901-5213 and the passcode is #19367094. A simultaneous webcast of the call can be accessed from the Investor Info page at www.rfindustries.com. A replay will be available after 2:00 p.m. EDT at this same Internet address. For a telephone replay, dial 888-286-8010, passcode #41930510, after 2:00 p.m. EDT.

About RF Industries

RFI manufactures, designs and distributes Radio Frequency (RF) connectors and cable assemblies, medical cabling products, RF wireless products, and fiber optic cable products. Coaxial connectors, cable assemblies and custom microwave RF connectors are used for Wi-Fi, PCS, radio, test instruments, computer networks, antenna devices, aerospace, OEM and Government agencies. Medical Cabling and Interconnector products are specialized custom electrical cabling products for the medical equipment monitoring market. RF Wireless products include digital data transceivers for industrial monitoring, wide area networks, GPS tracking and mobile wireless network solutions. Fiber optic cable, connector and harness products serve computer, aerospace, computer networking and specialty applications.

Safe Harbor Statements under the Private Securities Litigation Reform Act of 1995.

This press release contains forward-looking statements with respect to future events which are subject to a number of factors that could cause actual results to differ materially. Factors that could cause or contribute to such differences include, but are not limited to: changes in the telecommunications industry; the operations of the Cables Unlimited division which was acquired in June 2011; unexpected difficulties or delays in implementing the new wireless system upgrade to the Los Angeles County Fire Department’s existing remote communications equipment; and the Company’s reliance on certain distributors for a significant portion of anticipated revenues. Further discussion of these and other potential risk factors may be found in the Company’s public filings with the Securities and Exchange Commission (www.sec.gov), including its Form 10-K. All forward-looking statements are based upon information available to the Company on the date they are published and the Company undertakes no obligation to publicly update or revise any forward-looking statements to reflect events or new information after the date of this release.

RF INDUSTRIES, LTD.

PRELIMINARY CONDENSED CONSOLIDATED STATEMENTS OF INCOME

(in thousands, except per share and share amounts) (unaudited)

Three Months Ended

Nine Months Ended

July 31,

July 31,

2012

2011

2012

2011

Net sales

$

7,472

$

4,948

$

19,703

$

13,479

Cost of sales

4,119

2,532

10,825

6,657

Gross profit

3,353

2,416

8,878

6,822

Operating expenses:

Engineering

261

274

835

904

Selling and general

1,998

2,141

5,847

4,768

Total operating expenses

2,259

2,415

6,682

5,672

Operating income

1,094

1

2,196

1,150

Interest income

11

1

35

23

Income before provision for income taxes

1,105

2

2,231

1,173

Provision for income taxes

370

(63

)

776

350

Consolidated net income

735

65

1,455

823

Net income attributable to deconsolidation of VIE

—

1

2

1

Net income attributable to RF Industries & Subsidiary

$

735

$

64

$

1,453

$

822

Basic earnings per share:

Attributable to RF Industries & Subsidiary

$

0.11

$

0.01

$

0.21

$

0.13

Attributable to VIE

0.00

0.00

0.00

0.00

Consolidated basic earnings per share

$

0.11

$

0.01

$

0.21

$

0.13

Diluted earnings per share:

Attributable to RF Industries & Subsidiary

$

0.10

$

0.01

$

0.19

$

0.12

Attributable to VIE

0.00

0.00

0.00

0.00

Consolidated diluted earnings per share

$

0.10

$

0.01

$

0.19

$

0.12

Weighted average shares outstanding

Basic

6,867,073

6,486,577

6,914,450

6,131,944

Diluted

7,625,085

7,463,169

7,657,546

7,085,996

Dividends paid and payable

343,178

2,313,354

1,038,408

2,528,675

RF INDUSTRIES, LTD. AND SUBSIDIARY
PRELIMINARY CONDENSED CONSOLIDATED BALANCE SHEETS
(in thousands, except per share and share amounts)

Jul. 31, Oct. 31,
2012 2011
ASSETS (unaudited)

CURRENT ASSETS:
Cash and cash equivalents $ 5,630 $ 1,761
Restricted cash — 67
Certificates of deposit — 4,095
Trade accounts receivable, net 3,140 2,606
Inventories 6,756 6,189
Prepaid income taxes — 572
Other current assets 594 512
Deferred tax assets 611 611

TOTAL CURRENT ASSETS 16,731 16,413

Property and equipment, net 1,206 2,443
Goodwill 3,076 3,076
Amortizable intangible assets, net 1,682 1,866
Non-amortizable intangible assets 410 410
Note receivable from stockholder 67 67
Other assets 32 103

TOTAL ASSETS $ 23,204 $ 24,378

LIABILITIES AND STOCKHOLDERS’ EQUITY

CURRENT LIABILITIES:
Accounts payable $ 1,182 $ 521
Accrued expenses 1,691 1,580
Mortgages payable — 1,394
Income taxes payable 139 —

TOTAL CURRENT LIABILITIES 3,012 3,495

Deferred tax liabilities 1,072 1,072
Other long-term liabilities 26 133

TOTAL LIABILITIES 4,110 4,700

COMMITMENTS AND CONTINGENCIES

STOCKHOLDERS’ EQUITY:

Common stock – authorized 20,000,000 shares of $0.01 par value; 6,889,424 and 7,110,507 shares issued and outstanding
69 71
Additional paid-in capital 11,682 11,382
Retained earnings 7,343 8,011

Total RF Industries Ltd. and Subsidiary 19,094 19,464

Noncontrolling interest — 214

TOTAL EQUITY 19,094 19,678

TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY $ 23,204 $ 24,378

THIRD QUARTER SEGMENT SALES AND OPERATING INCOME
(in thousands) (unaudited)

RF Connector & Cables RF
Cable Assembly Unlimited Bioconnect Wireless Total

Fiscal 2012

Net sales $ 3,871 $ 2,728 $ 570 $ 304 $ 7,472
Operating Income 669 446 116 (138 ) 1,094

Fiscal 2011

Net Sales 3,274 909

(2)
510 255 4,948
Operating Income $ (99 )

(1)
$ 97 $ 121 $ (118 ) $

1

(1) Operating income in Q3 2011 was affected by $562,000 in non-recurring and other one-time expenses.

(2) Reflects partial quarter results from Cables Unlimited, acquired on June 15, 2011.

zeebox (CHYR) Becomes Charter Partner for Chyron ENGAGE Platform

AMSTERDAM, THE NETHERLANDS — (Marketwire) — 09/10/12 — At IBC2012 today, Chyron announced the integration of its ENGAGE second screen and social TV platform with the zeebox companion app and website that makes watching TV better. With seamless access to zeebox from within their existing Chyron graphics systems, broadcasters can cost-effectively leverage the leading second screen app to complement their live programming.

“The second screen applications running on tablets and other devices serve as an exciting new platform for publishing synchronized content that enhances the viewer’s experience,” said Jim Martinolich, vice president of integration technology at Chyron. “zeebox is the leading second screen app and its integration with our ENGAGE platform aids broadcasters in creating and managing second screen content without introducing significant new production costs. We are very excited to be adding zeebox to our list of ENGAGE charter partners.”

“Broadcasters are clamoring to embrace social TV and second-screen engagement, but the combination of fragmented market, myriad of consumer apps, and lack of integration with their existing workflow has — until now — made this a complex and expensive process,” said Anthony Rose, CTO and co-founder of zeebox. “By giving broadcasters the ability to publish directly into the zeebox platform using their existing tools and production workflow, we’re making it as easy for a broadcaster to create a play-along, social TV or interactive experience delivered within zeebox as it is to pop up an on-screen graphic — and that’s a huge game changer.”

ENGAGE gives broadcasters the ability to add viewer interactivity such as votes, polls, and tweet battles into their live news and sports programming, along with rich call-to-action graphics and infographics. By integrating with popular second screen and social data partners including zeebox, the Chyron platform eliminates the need for custom integration while allowing broadcasters to maintain their routine production workflows. zeebox boosts the ability of broadcasters to offer TV programming that grabs the attention of viewers and fuels greater interactivity. The app gives broadcasters a single program-based destination where fans can chat, share, and interact.

Within the Chyron graphics workflow, the zeebox companion app becomes another layer of rich informational graphics, driven by the newsroom rundown or by the live sports graphics team using the same tools they rely on for daily production. The second screen graphics are created in Chyron’s Lyric graphics creation software, share the same look as the station or group’s on-screen graphics, and are fed by the same sports data feeds that feed on-air programming. Users can even decide on-the-fly which graphics go to air and which graphics go to the second screen.

Chyron will demonstrate the use of zeebox and ENGAGE throughout IBC2012 at its stand 7.D11. More information about Chyron products is available at www.chyron.com.

About zeebox
zeebox is the new, social, interactive and immersive way to watch TV. It turns your smartphone, tablet or laptop into an interactive companion that enables consumers to engage with friends around TV shows, to buy what they see on screen, to remote control their TV, and to get more information about whatever program they’re watching including access to exclusive interactive content.

By partnering with zeebox, broadcasters and content owners can augment their TV shows on the second screen, engage interactively with fans, and monetize this new medium in synch with live TV.

zeebox was founded in 2011 by former iPlayer CTO Anthony Rose and EMI executive Ernesto Schmitt. The company is headquartered in Covent Garden, London, and is expanding rapidly into other countries.

zeebox Press enquiries: hello@zeebox.com

About Chyron
Chyron (NASDAQ: CHYR) is a leading provider of Graphics as a Service for on-air and digital video applications including newsrooms, studios, sports broadcasting facilities, and corporate video environments. An Emmy® Award-winning company whose products have defined the world of digital and broadcast graphics, Chyron’s graphics solutions include the Axis World Graphics online content creation software and order management system, on-air graphics systems, clip servers, channel branding, and graphics asset management solutions, all of which may be incorporated into the company’s BlueNet™ end-to-end graphics workflow. More information about Chyron products and services is available on the company websites: www.chyron.com and www.axisgraphics.tv. The company’s investor relations information is at www.chyron.com via the “Investors” link.

All trademarks and registered trademarks mentioned herein are the property of their respective owners.

Blog: http://chyronchat.com
Facebook: http://www.facebook.com/chyronmelville
LinkedIn: http://www.linkedin.com/company/chyron
Twitter: http://twitter.com/chyronmelville
Tumblr: http://chyronmelville.tumblr.com/
User Forum: http://forum.chyron.com/vbb/index.php
YouTube: http://www.youtube.com/user/chyronmelville
Pinterest: http://pinterest.com/chyron/

Visit Chyron at IBC2012, Stand 7.D11

Photo Link: www.wallstcom.com/Chyron/zeebox.zip

Chyron Contact:
Allyson Patanella
Marketing/PR Coordinator
Tel: +1 (631) 845-2102
Email: apatanella@chyron.com

Agency Contact:
Sarah Schraad
Wall Street Communications
Tel: +1 (303) 567-4048
Email: sarah@wallstcom.com

Optical Cable Corp. (OCC) Reports Fiscal Third Quarter 2012 Financial Results

OCC® Achieves Increases in Net Sales, Gross Profit and Net Income

ROANOKE, Va., Sept. 10, 2012 /PRNewswire/ — Optical Cable Corporation (Nasdaq GM: OCC) (“OCC®” or the “Company”) today announced financial results for its fiscal third quarter ended July 31, 2012. The Company achieved significant increases in net sales, gross profit and net income for both the quarter and year-to-date periods, compared to the same periods in fiscal year 2011.

OCC’s increased sales and strong operating leverage resulted in net income attributable to OCC during the third quarter of fiscal 2012 of almost ten times that of the same period in 2011 and net income attributable to OCC for the year-to-date period in 2012 of more than five times that of the same period in 2011.

Third Quarter 2012 Financial Results

OCC’s consolidated net sales increased 17.2% to $22.0 million for the third quarter of fiscal 2012, compared to consolidated net sales of $18.8 million for the same period last year. The increase in net sales during the third quarter was attributable to increased sales of the Company’s fiber optic cable products.

OCC’s gross profit increased 35.0% to $8.8 million in the third quarter of fiscal 2012, compared to $6.5 million in the third quarter of fiscal year 2011. Gross profit margin, or gross profit as a percentage of net sales, increased to 39.9% in the third quarter of fiscal 2012 from 34.7% in the third quarter of fiscal year 2011.

OCC recorded net income attributable to the Company of $1.2 million, or $0.18 per basic and diluted share, for the third quarter of fiscal 2012, compared to $118,000, or $0.02 per basic and diluted share, for the third quarter of fiscal 2011.

Fiscal Year-to-Date 2012 Financial Results

OCC’s consolidated net sales increased 14.4% to $61.4 million for the first nine months of fiscal 2012, compared to net sales of $53.7 million for the same period last year. The increase in net sales was attributable to increased sales of the Company’s fiber optic cable products.

Gross profit increased 26.1% to $23.8 million in the first nine months of fiscal 2012, compared to $18.9 million in the first nine months of fiscal 2011. Gross profit margin increased to 38.8% in the first nine months of fiscal 2012 from 35.2% in the first nine months of fiscal 2011.

OCC recorded net income attributable to the Company of $2.3 million, or $0.36 per basic and diluted share, for the first nine months of fiscal year 2012, compared to $430,000, or $0.07 per basic and diluted share, for the same period in fiscal year 2011.

Management’s Comments

Neil Wilkin, President and Chief Executive Officer of OCC, said “We are pleased with OCC’s strong sales and earnings performance, as sales of our fiber optic cable products continue to drive top-line growth. In our third quarter, OCC again demonstrated that our operating leverage allows us to deliver disproportionate earnings growth rates relative to our net sales growth rates as fixed costs are spread over larger sales volumes. In addition, we continue to maintain a strong balance sheet and return capital to shareholders through a regular quarterly dividend.”

Mr. Wilkin added, “OCC has a solid sales order forward load, and we expect our sales strength will continue in our fourth fiscal quarter, despite economic weakness. We will continue to execute our strategy to grow OCC and to deliver enhanced shareholder value, and we look forward to a strong finish to our fiscal year.”

Conference Call Information

As previously announced, OCC will host a conference call today, Monday, September 10, 2012, at 10:00 a.m. Eastern Time. Individuals wishing to participate in the conference call should call (888) 868-9083 or (973) 935-8512. For interested individuals unable to join the call, a replay will be available through September 17, 2012 by dialing (800) 585-8367 or (404) 537-3406, pass code 25486985. The call will also be broadcast live over the Internet and can be accessed by visiting the investor relations section of the Company’s website at www.occfiber.com.

Company Information

Optical Cable Corporation (“OCC®”) is a leading manufacturer of a broad range of fiber optic and copper data communications cabling and connectivity solutions primarily for the enterprise market, offering an integrated suite of high quality, warranted products which operate as a system solution or seamlessly integrate with other providers’ offerings. OCC’s product offerings include designs for uses ranging from commercial, enterprise network, datacenter, residential and campus installations to customized products for specialty applications and harsh environments, including military, industrial, mining and broadcast applications. OCC products include fiber optic and copper cabling, fiber optic and copper connectors, specialty fiber optic and copper connectors, fiber optic and copper patch cords, pre-terminated fiber optic and copper cable assemblies, racks, cabinets, datacom enclosures, patch panels, face plates, multi-media boxes and other cable and connectivity management accessories, and are designed to meet the most demanding needs of end-users, delivering a high degree of reliability and outstanding performance characteristics.

OCC® is internationally recognized for pioneering the design and production of fiber optic cables for the most demanding military field applications, as well as of fiber optic cables suitable for both indoor and outdoor use, and creating a broad product offering built on the evolution of these fundamental technologies. OCC also is internationally recognized for its role in establishing copper connectivity data communications standards, through its innovative and patented technologies.

Founded in 1983, OCC is headquartered in Roanoke, Virginia with offices, manufacturing and warehouse facilities located in each of Roanoke, Virginia, near Asheville, North Carolina and near Dallas, Texas. OCC primarily manufactures its fiber optic cables at its Roanoke facility which is ISO 9001:2008 registered and MIL-STD-790F certified, its enterprise connectivity products at its Asheville facility which is ISO 9001:2008 registered, and its military and harsh environment connectivity products and systems at its Dallas facility which is ISO 9001:2008 registered and MIL-STD-790F certified.

Optical Cable Corporation, OCC, Superior Modular Products, SMP Data Communications, Applied Optical Systems, and associated logos are trademarks of Optical Cable Corporation.

Further information about OCC® is available on the Internet at www.occfiber.com.

FORWARD-LOOKING INFORMATION

This news release by Optical Cable Corporation and its subsidiaries (collectively, the “Company” or “OCC”) may contain certain forward-looking information within the meaning of the federal securities laws. The forward-looking information may include, among other information, (i) statements concerning our outlook for the future, (ii) statements of belief, anticipation or expectation, (iii) future plans, strategies or anticipated events, and (iv) similar information and statements concerning matters that are not historical facts. Such forward-looking information is subject to known and unknown variables, uncertainties, contingencies and risks that may cause actual events or results to differ materially from our expectations, and such known and unknown variables, uncertainties, contingencies and risks may also adversely affect Optical Cable Corporation and its subsidiaries, the Company’s future results of operations and future financial condition, and/or the future equity value of the Company. A partial list of such variables, uncertainties, contingencies and risks that could cause or contribute to such differences from our expectations or that could otherwise adversely affect Optical Cable Corporation and its subsidiaries is set forth in Optical Cable Corporation’s quarterly and annual reports filed with the Securities and Exchange Commission (“SEC”) under the heading “Forward-Looking Information.” OCC’s quarterly and annual reports are available to the public on the SEC’s website at http://www.sec.gov. In providing forward-looking information, the Company expressly disclaims any obligation to update this information, whether as a result of new information, future events or otherwise except as required by applicable laws and regulations.

(Financial Tables Follow)

OPTICAL CABLE CORPORATION
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(thousands, except per share data)
(unaudited)

Three Months Ended

Nine Months Ended

July 31,

July 31,

2012

2011

2012

2011

Net sales

$ 22,004

$ 18,775

$ 61,389

$ 53,672

Cost of goods sold

13,217

12,266

37,591

34,795

Gross profit

8,787

6,509

23,798

18,877

SG&A expenses

6,898

6,228

20,273

18,288

Royalty income, net

(22)

(247)

(310)

(645)

Amortization of intangible assets

34

108

101

323

Income from operations

1,877

420

3,734

911

Interest expense, net

(144)

(146)

(427)

(474)

Other, net

(1)

(22)

(4)

14

Other expense, net

(145)

(168)

(431)

(460)

Income before income taxes

1,732

252

3,303

451

Income tax expense

554

178

1,065

175

Net income

$ 1,178

$ 74

$ 2,238

$ 276

Net income (loss) attributable to

Noncontrolling interest

5

(44)

(77)

(154)

Net income attributable to OCC

$ 1,173

$ 118

$ 2,315

$ 430

Net income attributable to OCC

per share: Basic and diluted

$ 0.18

$ 0.02

$ 0.36

$ 0.07

Weighted average shares outstanding:

Basic and diluted

6,667

6,391

6,449

6,306

Cash dividends declared per common share

$ 0.015

$ 0.01

$ 0.045

$ 0.03

OPTICAL CABLE CORPORATION
CONDENSED CONSOLIDATED BALANCE SHEET DATA
(thousands)
(unaudited)

July 31,

October 31,

2012

2011

Cash

$ 1,206

$ 1,092

Trade accounts receivable, net

13,359

10,798

Inventories

19,032

16,497

Other current assets

2,737

3,136

Total current assets

36,334

31,523

Non-current assets

12,674

13,422

Total assets

$ 49,008

$ 44,945

Current liabilities

$ 9,137

$ 8,197

Non-current liabilities

10,184

9,025

Total liabilities

19,321

17,222

Total shareholders’ equity attributable to OCC

30,250

28,209

Noncontrolling interest

(563)

(486)

Total shareholders’ equity

29,687

27,723

Total liabilities and shareholders’ equity

$ 49,008

$ 44,945

AT THE COMPANY:

Neil Wilkin

Tracy Smith

Chairman, President & CEO

Senior Vice President & CFO

(540) 265-0690

(540) 265-0690

investorrelations@occfiber.com

investorrelations@occfiber.com

AT JOELE FRANK, WILKINSON BRIMMER KATCHER:

Andrew Siegel

Aaron Palash

(212) 355-4449 ext. 127

(212) 355-4449 ext. 103

occ-jfwbk@joelefrank.com

occ-jfwbk@joelefrank.com

SOURCE Optical Cable Corporation

Neuralstem (CUR) President And CEO To Present At The 2012 Rodman & Renshaw Conference

Live Webcast on Tuesday, September 11 at 2:00 p.m. EDT

ROCKVILLE, Md., Sept. 10, 2012 /PRNewswire/ — Neuralstem, Inc. (NYSE MKT: CUR) announced that President and CEO Richard Garr will present at the 2012 Rodman & Renshaw Annual Healthcare Conference on Tuesday, September 11 at 2:00 p.m. EDT, at The Waldorf=Astoria, Starlight South. Garr will discuss the company’s opportunities and advancements in neural stem cell therapy and pharmaceuticals. He will be providing an update on ongoing clinical trials, including the recently completed ALS Phase I, and an overview on future trials. To view the live webcast, visit Neuralstem’s Investor Center at www.neuralstem.com , or: http://www.wsw.com/webcast/rrshq22/cur .

(Logo: http://photos.prnewswire.com/prnh/20061221/DCTH007LOGO )

The 2012 Rodman & Renshaw Annual Healthcare Conference is being held at The Waldorf=Astoria in New York City, September 9-11. For more information, see: http://www.rodm.com/conferences?id=176 .

About Neuralstem

Neuralstem’s patented technology enables the ability to produce neural stem cells of the human brain and spinal cord in commercial quantities, and the ability to control the differentiation of these cells constitutively into mature, physiologically relevant human neurons and glia. Neuralstem has recently completed an FDA-approved Phase I safety clinical trial for amyotrophic lateral sclerosis (ALS), often referred to as Lou Gehrig’s disease, and has been awarded orphan status designation by the FDA.

In addition to ALS, the company is also targeting major central nervous system conditions with its NSI-566 cell therapy platform, including spinal cord injury, ischemic spastic paraplegia and chronic stroke. The company has submitted an IND (Investigational New Drug) application to the FDA for a Phase I safety trial in chronic spinal cord injury.

Neuralstem also has the ability to generate stable human neural stem cell lines suitable for the systematic screening of large chemical libraries. Through this proprietary screening technology, Neuralstem has discovered and patented compounds that may stimulate the brain’s capacity to generate new neurons, possibly reversing the pathologies of some central nervous system conditions. The company is in a Phase Ib safety trial evaluating NSI-189, its first neurogenic small molecule compound, for the treatment of major depressive disorder (MDD). Additional indications could include chronic traumatic encephalopathy (CTE), Alzheimer’s disease, and post-traumatic stress disorder (PTSD).

For more information, please visit www.neuralstem.com or connect with us on Twitter and Facebook.

Cautionary Statement Regarding Forward Looking Information

This news release may contain forward-looking statements made pursuant to the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that such forward-looking statements in this press release regarding potential applications of Neuralstem’s technologies constitute forward-looking statements that involve risks and uncertainties, including, without limitation, risks inherent in the development and commercialization of potential products, uncertainty of clinical trial results or regulatory approvals or clearances, need for future capital, dependence upon collaborators and maintenance of our intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in Neuralstem’s periodic reports, including the annual report on Form 10-K for the year ended December 31, 2011 and the quarterly report on Form 10-Q for the period ended June 30, 2012.

SOURCE Neuralstem, Inc.

KSW, Inc. (KSW) to Be Acquired by Related Companies

LONG ISLAND CITY, NY and NEW YORK, NY — (Marketwire) — 09/10/12 — KSW, Inc. (NASDAQ: KSW) (“KSW”), a provider of heating, ventilating and air conditioning (HVAC) systems and process piping systems for institutional, industrial, commercial, high-rise residential and public works projects, and Related Companies, a fully-integrated, highly diversified real estate firm with experience in every aspect of real estate development, acquisitions, management, finance, marketing and sales, today announced that they have entered into a definitive merger agreement.

Under the terms of the agreement, a subsidiary of Related Companies (“Merger Sub”) will acquire all of the outstanding shares of common stock of KSW for $5.00 per share in cash through a cash tender offer followed by a merger. The transaction is valued in the aggregate at approximately $32.1 million. The cash consideration represents a premium of approximately 23% to KSW’s closing share price on September 7, 2012, the last trading day before KSW publicly announced the merger. The agreement has been unanimously approved by KSW’s Board of Directors.

Floyd Warkol, CEO of KSW, commented, “We are pleased to announce this merger as it delivers significant value to our shareholders. KSW has enjoyed a long and successful relationship with Related Companies while working on their New York City projects. Partnering with Related Companies will only enhance our ability to provide first quality services to our current and future customers.”

Bruce A. Beal, Jr., President of Related Companies, said, “As a vertically- integrated developer working across all asset classes we are consistently looking for opportunities to enhance our developments and increase our efficiency. The acquisition of KSW, a best-in-class HVAC provider with an experienced management team, allows us to utilize their skill set throughout the design process, offers direct purchasing capability from equipment manufacturers, and creates an even more direct link to New York City’s talented workforce. It will also allow us to continue to pioneer new innovations in sustainability, customizing and developing new sustainable features for our robust pipeline of projects.”

Under the terms of the merger agreement, the parties anticipate that Merger Sub will commence a tender offer for all of the outstanding shares of KSW before September 21, 2012. If the first step tender offer is successfully completed, Merger Sub will acquire any of the KSW shares of common stock not tendered in the tender offer through a second step merger transaction in which the remaining KSW shares are converted into a right to receive the same consideration per share as paid in the tender offer. The tender offer transaction, which is subject to customary closing conditions, is expected to close by October 26, 2012.

Completion of the tender offer is subject to, among other things, the satisfaction of the minimum tender condition of at least a majority of KSW’s outstanding shares of common stock on a fully diluted basis, and other customary closing conditions. The transaction is not subject to a financing condition.

About Related Companies

Related Companies is the most prominent privately-owned real estate firm in the United States. Formed 40 years ago, Related is a fully-integrated, highly diversified real estate firm with experience in every aspect of development, acquisitions, management, finance, marketing and sales. Headquartered in New York City, Related has offices and major developments in Boston, Chicago, Los Angeles, San Francisco, South Florida, Abu Dhabi and Shanghai and boasts a team of approximately 2,000 professionals. The Company’s existing portfolio of real estate assets, valued at over $15 billion, is made up of best-in-class mixed-use, residential, retail, office, trade show and affordable properties in premier high-barrier-to-entry markets. For more information about Related Companies please visit www.related.com.

About KSW

KSW, Inc., through its wholly-owned subsidiary, KSW Mechanical Services, Inc., furnishes and installs heating, ventilating and air conditioning (HVAC) systems and process piping systems for institutional, industrial, commercial, high-rise residential and public works projects. KSW Mechanical Services, Inc. also acts as Trade Manager on larger construction projects, such as the Mt. Sinai Center for Science and Medicine.

Important Information about the Tender Offer

This press release is not an offer to purchase or a solicitation of an offer to sell securities of KSW. The planned tender offer by Merger Sub for all of the outstanding shares of common stock of KSW has not yet commenced. Following the commencement of the tender offer, Merger Sub will mail to KSW stockholders an offer to purchase and related materials and KSW will mail to its stockholders a solicitation/recommendation statement with respect to the tender offer. At the time the offer is commenced, Merger Sub will file a tender offer statement with the U.S. Securities and Exchange Commission (the “SEC”) on Schedule TO, and KSW will file a solicitation/recommendation statement with the SEC on Schedule 14D-9 with respect to the tender offer. Investors and KSW stockholders are strongly advised to read these materials in their entirety (including an offer to purchase, a related letter of transmittal and other offer documents) and the solicitation/recommendation statement when they become available, since they will contain important information that should be considered before any decision is made with respect to the tender offer. KSW stockholders may obtain a free copy of these materials when they become available and other documents filed by Merger Sub or KSW with the SEC at the website maintained by the SEC at www.sec.gov. These materials also may be obtained when they become available for free by contacting the information agent for the tender offer.

Advisors

DLA Piper LLP is acting as legal advisor to Related Companies and Merger Sub. KSW engaged Sandler O’Neill as financial advisor and Bracewell & Giuliani LLP as legal advisor for the transaction.

Cautionary Statements

Statements in this press release that are not historical, including statements regarding KSW’s beliefs, expectations, and strategies, constitute “forward looking statements” within the meaning of the federal securities laws. These statements are subject to risks and uncertainties that could cause actual results to differ materially from those expressed in the forward-looking statements. Important factors that could cause the differences are discussed in KSW’s reports on Forms 10-Q, 10-K, and 8-K that it periodically files with the Securities and Exchange Commission. These factors include KSW’s sales process and market acceptance of its products and services, KSW’s capital needs, KSW’s dependence on significant customers and suppliers, risks of a new product offering, risks that KSW may incur significant costs related to self-insurance retention levels for employee benefits and workers’ compensation programs, and the competitive healthcare marketplace. KSW does not undertake to update any forward-looking statements in this press release. Copies of KSW’s SEC filings, including its annual report on Form 10-K and quarterly reports on Form 10-Q, may be obtained by contacting KSW’s general counsel at (718) 340-1409 or at the SEC Filings section of its website at www.kswmechanical.com.

Media/Investor Contacts

For KSW, Inc.:

James F. Oliviero
(718) 340-1409

For Related Companies:

Joanna Rose
(212) 801-3902

Cell Therapeutics (CTI) to update Pixuvri® status at Rodman & Renshaw

Cell Therapeutics, Inc. (CTI) to update Pixuvri® launch and pacritinib pivotal trial status at the Annual Rodman & Renshaw Global Investment Conference

SEATTLE, Sept. 7, 2012 /PRNewswire/ — Cell Therapeutics, Inc. (CTI) (NASDAQ and MTA: CTIC) management will present at the Annual Rodman & Renshaw Global Investment Conference on Tuesday, September 11at 10:25 a.m. Eastern/ 4:25 p.m. Central European/ 7:25 a.m. Pacific time in the Starlight North room of the Waldorf-Astoria Hotel.

The presentation with slides will be webcast live and available for replay after the presentation. The webcast can be accessed at www.celltherapeutics.com.

Annual Rodman & Renshaw Global Investment Conference

CTI presentation: Tuesday, September 11, 2012

10:25 a.m. Eastern/ 4:25 p.m. Central European/ 7:25 a.m. Pacific

Starlight North, Waldorf-Astoria Hotel

Media contact:

Investors contact:

Cell Therapeutics, Inc.

Cell Therapeutics, Inc.

Dan Eramian

Ed Bell

T: 206.272.4343

T: 206.272.4345

F: 206.272.4434

E: invest@ctiseattle.com

E: deramian@ctiseattle.com

www.celltherapeutics.com/investors

www.celltherapeutics.com/press_room

Interim Data From Peregrine’s (PPHM) Phase II Lung Cancer Trial Doubles Survival

Interim Data From Peregrine’s Phase II Trial in Second-Line Non-Small Cell Lung Cancer Demonstrate Doubling of Median Overall Survival in Bavitiximab-Containing Arms

TUSTIN, CA — (Marketwire) — 09/07/12 —

Interim Data from Double-Blind, Placebo-Controlled Trial Presented at Late-Breaking Plenary Session at Leading Oncology Symposium

Data Show Statistically Significant Improvement in Overall Survival for Patients Receiving Bavituximab Plus Docetaxel Versus Docetaxel Alone

Clinical Data Strongly Support Advancing Program into Phase III Clinical Development

Company to Host Conference Call on Monday, September 10, at 11:00 AM EDT

Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM), today announced that interim results were presented from its 121 patient randomized, double-blind, placebo-controlled Phase IIb trial in patients with refractory non-small cell lung cancer (NSCLC). The blinded study evaluated two dose levels of bavituximab (bavituximab-containing arms) given with docetaxel versus docetaxel plus placebo (control arm). The interim data showed a statistically significant improvement in overall survival (Hazard Ratio 0.524, p-value .0154) and a doubling of median overall survival (OS) in the bavituximab-containing arms compared to the control arm. The following interim data was presented as part of a late-breaking plenary presentation at the 2012 Chicago Multidisciplinary Symposium in Thoracic Oncology by David Gerber, M.D., Associate Professor of Internal Medicine at the University of Texas Southwestern Medical Center, a principal investigator in the trial.

—————————————————————————-
Treatment Arm
—————————————————————————-
Bavituximab Bavituximab Bavituximab
Placebo (1 mg/kg) (3 mg/kg) (Pooled Data)
plus docetaxel plus docetaxel plus docetaxel plus docetaxel
—————————————————————————-
Number of
patients (per
protocol 38 40 39 79
population)
—————————————————————————-
Median Overall
Surviva lHazard 5.6 months 11.1 months 13.1 months 12.1 months
Ratio (p-value) — .512 (.0286) .539 (.0714) .524 (.0154)
—————————————————————————-
Overall Response 7.9% 15% 17.9% 16.5%
Ratep-value — .3262 .1895 .2069
—————————————————————————-
Progression Free
Survival Hazard 3.0 months 4.2 months 4.5 months 4.2 months
Ratio (p-value) — .571 (.0794) .65 (.1921) .605 (.067)
—————————————————————————-

“This study was a rigorous trial designed to minimize bias and we are encouraged that this trial yielded such positive results in the most important endpoint, overall survival. The positive overall response rates and progression free survival in both bavituximab-containing arms seen earlier in the study has now translated into a statistically significant extension in overall survival for patients, a result rarely achieved in phase II clinical trials.” said Joseph Shan, vice president of clinical and regulatory affairs at Peregrine. “The quality of this data gives us a solid foundation for designing a phase III trial with an increased probability of success. We are planning for an end-of-phase II meeting with the FDA as we plan to initiate this trial by mid-2013.”

The trial enrolled 121 patients (117 evaluable per the study protocol) with second-line non-squamous NSCLC following one prior chemotherapy regimen at over 40 clinical centers. Patients were equally randomized to 1 of the 3 treatment arms, docetaxel (75mg/m2) plus either placebo, 1 mg/kg bavituximab, or 3 mg/kg bavituximab until disease progression. Approximately 50% of the patients were enrolled in the U.S. and 50% were enrolled internationally with equal distribution between all treatment groups.

“Robust data from this Phase II trial clearly demonstrate a significant benefit in overall survival with a good safety profile in patients receiving bavituximab plus docetaxel compared to those receiving docetaxel plus placebo,” said Steven W. King, president and chief executive officer of Peregrine. “We are currently in discussions with several potential pharmaceutical partners who have expressed great interest in our bavituximab oncology program. It is our goal to identify the optimal partner to assist with the design and logistics of a multinational Phase III pivotal trial.”

The interim results from the study showed no significant safety differences between the three treatment arms as determined by the trial’s independent data monitoring committee. Baseline characteristics were well balanced across all three treatment arms of the study, including performance (ECOG) status, age, gender, and race. Tumor responses were determined in accordance with Response Evaluation Criteria In Solid Tumors (RECIST 1.1) based on blinded central radiology review.

“The median overall survival results from the Proof-of Concept study are truly outstanding and great news for patients. Statistically significant overall survival results at this stage of development are rare and have put us in an excellent position for advancing the program. Our attention is now turned to an end of phase II meeting by year end which will help us define the most efficient path forward to potential regulatory approval,” said Robert Garnick, PhD, head of regulatory affairs at Peregrine. “A global Phase III trial designed very similarly to the robust design of this Phase II trial greatly increases bavituximab’s likelihood of success.”

Audio Webcast
In conjunction with Dr. Gerber’s presentation in Chicago, Peregrine has posted an audio webcast and slide deck to Peregrine’s website. The webcast will be hosted by Joseph Shan, vice president of clinical and regulatory affairs. This event will be pre-recorded. Access to the audio and corresponding slides can be found on Peregrine’s website.

Conference Call
Peregrine will host a conference call and webcast to discuss these data and financial results for the first quarter fiscal year 2013 on Monday, September 10, 2012, at 11:00 AM ET (8:00 AM PT). To listen to the conference call, please dial (877) 312-5443 or (253) 237-1126 and request the Peregrine Pharmaceuticals call. A replay of the call will be available starting approximately two hours after the conclusion of the call through September 24, 2012 by calling (855) 859-2056, or (404) 537-3406 and using passcode 27367274.

About Lung Cancer
According to the American Cancer Society, lung cancer is the second most commonly diagnosed cancer in the U.S., with approximately 226,160 new cases and 160,340 deaths each year, representing approximately 28% of all cancer deaths. NSCLC is the most common type of lung cancer, accounting for approximately 85-90% of lung cancer cases. Unfortunately, the five-year survival rate for NSCLC patients is only 1%.

About Bavituximab
Bavituximab is a first-in-class phosphatidylserine (PS)-targeting monoclonal antibody that represents a new approach to treating cancer. Bavituximab is the lead drug candidate from the company’s PS technology platform and is currently being tested in eight clinical trials including three randomized Phase II trials in front-line and second-line non-small cell lung cancer, front-line pancreatic cancer and five investigator-sponsored trials (ISTs) in additional oncology indications.

PS is a highly immunosuppressive molecule usually located inside the membrane of healthy cells, but “flips” and becomes exposed on the outside of cells that line tumor blood vessels, creating a specific target for anti-cancer treatments. PS-targeting antibodies target and bind to PS and block this immunosuppressive signal, thereby enabling the immune system to recognize and fight the tumor.

About Peregrine Pharmaceuticals
Peregrine Pharmaceuticals, Inc. is a biopharmaceutical company with a portfolio of innovative monoclonal antibodies in clinical trials focused on the treatment and diagnosis of cancer. The company is pursuing multiple clinical programs in cancer with its lead product candidate bavituximab and novel brain cancer agent Cotara®. Peregrine also has in-house cGMP manufacturing capabilities through its wholly-owned subsidiary Avid Bioservices, Inc. (www.avidbio.com), which provides development and biomanufacturing services for both Peregrine and outside customers. Additional information about Peregrine can be found at www.peregrineinc.com.

Safe Harbor Statement: Statements in this press release which are not purely historical, including statements regarding Peregrine Pharmaceuticals’ intentions, hopes, beliefs, expectations, representations, projections, plans or predictions of the future are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The forward-looking statements involve risks and uncertainties including, but not limited to, the risk that the overall survival data together with the above reported data may not support registration filings with the U.S. Food and Drug Administration, the risk that overall survival data from the planned Phase III trial will not be consistent with the results from the randomized, double-blind, placebo-controlled Phase IIb trial, the risk that results from the other randomized Phase II trial will not be consistent with results experienced in the earlier single-arm Phase II trial or support registration filings with the FDA, and the risk that Peregrine may not have or raise adequate financial resources to complete the planned clinical programs. Factors that could cause actual results to differ materially or otherwise adversely impact the company’s ability to obtain regulatory approval for its product candidates include, but are not limited to, uncertainties associated with completing preclinical and clinical trials for our technologies; the early stage of product development; the significant costs to develop our products as all of our products are currently in development, preclinical studies or clinical trials; obtaining additional financing to support our operations and the development of our products; obtaining regulatory approval for our technologies; anticipated timing of regulatory filings and the potential success in gaining regulatory approval and complying with governmental regulations applicable to our business. Our business could be affected by a number of other factors, including the risk factors listed from time to time in the company’s SEC reports including, but not limited to, the annual report on Form 10-K for the year ended April 30, 2012. The company cautions investors not to place undue reliance on the forward-looking statements contained in this press release. Peregrine Pharmaceuticals, Inc. disclaims any obligation, and does not undertake to update or revise any forward-looking statements in this press release.

Image Available: http://www2.marketwire.com/mw/frame_mw?attachid=2086681

Add to Digg Bookmark with del.icio.us Add to Newsvine

Contact:
Christopher Keenan or Jay Carlson
Peregrine Pharmaceuticals, Inc.
(800) 987-8256
info@peregrineinc.com

Dataram (DRAM) Executes Agreement with AMD for Radeon RAMDisk

Dataram Corporation [NASDAQ: DRAM], a leading international manufacturer of computer memory, storage and software products, announced today that it has entered into a formal agreement with AMD (NYSE: AMD) to develop an AMD-branded version of Dataram’s popular RAMDisk software. Dataram will market the product under the name Radeon RAMDisk and will target gaming enthusiasts seeking exponential improvements in game load times leading to an enhanced gaming experience. AMD intends to offer special Radeon RAMDisk incentives for those purchasing AMD Value, Entertainment, Performance and Radeon Edition memory products.

With over four million downloads of RAMDisk occurring since its launch in 2000, Dataram’s RAMDisk software is recognized as a leader in the RAM drive software market. In addition to being used extensively by gaming enthusiasts, the software is also widely used for accelerating database access, speeding up internet browsing, substantially reducing video rendering times, reducing wear on SSDs and reducing software development cycles.

RAMDisk use has recently stirred great interest and expanded into corporate environments for accelerating specific applications and is being integrated into other commercially available products for which performance is critical. Quality and reliability, a hallmark of Dataram’s enterprise-grade memory products, is a key characteristic of its RAMDisk software that contributes to its exceptional recognition in the market.

“Dataram RAMDisk is one of the top RAMDisk software products in the Windows market. With the increase in memory capacity and reduced cost per gigabyte, now is the best time ever to utilize DRAM to create a lightning fast disk drive. Like all Dataram products, we have not only focused on speed and value, we have applied years of experience with data protection and reliability,” said Jason Caulkins, Dataram Chief Technologist.

Various benchmarks have shown that using RAMDisk results in up to 525% faster game load times, substantially improving the gaming experience. Used in conjunction with AMD memory products, gaming enthusiasts can gain distinct advantages when competing against their fellow gamers. Commenting on the launch of the AMD Radeon™ RAMDisk product in early fourth quarter, Roman Kyrychynskyi, Product Director at AMD said, “With the importance that memory plays in the overall PC experience, eliminating bottlenecks is crucial for avid PC gamers. Our collaboration with Dataram looks to provide the answer with an enhanced storage solution that reduces possible performance plateaus and provide a superior PC gaming experience.”

As RAMDisk continues to gain rapid consumer and commercial recognition, focus will be applied to rolling out the strategic product roadmap for RAMDisk. Particular focus will be directed towards expanding those markets that have already adopted and recognized the value of using Dataram’s RAMDisk.

About Dataram

Founded in 1967, Dataram is a worldwide leader in the manufacture of high-quality computer memory, storage and software products. Our products and services deliver IT infrastructure optimization, dramatically increase application performance and deliver substantial cost savings. Dataram solutions are deployed in 70 Fortune 100 companies and in mission-critical government and defense applications around the world. For more information about Dataram, visit www.dataram.com.

About AMD

AMD (NYSE: AMD) is a semiconductor design innovator leading the next era of vivid digital experiences with its groundbreaking AMD Accelerated Processing Units (APUs) that power a wide range of computing devices. AMD’s server computing products are focused on driving industry-leading cloud computing and virtualization environments. AMD’s superior graphics technologies are found in a variety of solutions ranging from game consoles, PCs to supercomputers. For more information, visit http://www.amd.com.

All names are trademarks or registered trademarks of their respective owners.

The information provided in this press release may include forward-looking statements relating to future events, such as the development of new products, pricing and availability of raw materials or the future financial performance of the Company. Actual results may differ from such projections and are subject to certain risks including, without limitation, risks arising from: changes in the price of memory chips, changes in the demand for memory systems, increased competition in the memory systems industry, order cancellations, delays in developing and commercializing new products and other factors described in the Company’s most recent Annual Report on Form 10-K, filed with the Securities and Exchange Commission, which can be reviewed at www.sec.gov.

Duma Energy (DUMA) Namibian Government Grants Exploration License on 5.3 Million Acre Concession

HOUSTON, Sept. 6, 2012 (GLOBE NEWSWIRE) — Duma Energy Corp. (OTCBB:DUMA) is pleased to announce that it has completed the share exchange agreement, dated August 7, 2012 (the “Agreement”) with Namibia Exploration, Inc. (“NEI”); the “Acquisition”. As a result of the completion of the Acquisition, NEI became a wholly owned subsidiary of Duma.

Duma, indirectly through NEI, has received a 39% working interest (43.33% cost responsibility) in an onshore African petroleum concession (the “Concession”) located in the Republic of Namibia which is approximately 5.3 million acres in size covered by Petroleum Exploration License No. 0038 issued by the Republic of Namibia Ministry of Mines and Energy. Duma holds its indirect working interest in the Concession in partnership with the National Petroleum Corporation of Namibia Ltd. (“NPC Namibia”) and Hydrocarb Namibia Energy Corporation (“Hydrocarb Namibia”), a company chartered in the Republic of Namibia and which is a majority owned subsidiary of Hydrocarb Corporation (“Hydrocarb”), a company organized under the laws of the State of Nevada, USA. Hydrocarb Namibia, as operator of the Concession, holds at 51% working interest (56.67% cost responsibility) in the Concession and NPC Namibia holds a 10% carried working interest in the Concession.

“The timely issuance of the concession license by the government of Namibia allows us now to begin focusing our efforts on the task of exploring our massive concession, which is roughly the size of the state of Massachusetts,” stated Jeremy G. Driver, Chairman and CEO of Duma Energy Corp. Driver added, “We are excited to move forward with the exploration phase in Namibia and are encouraged by the geological progress and findings so far.”

Pasquale Scaturro, Hydrocarb’s President and Chief Operating Officer stated, “There are few governments in Africa that can match the transparency and professionalism of Namibia. We are truly pleased to have such a large and premium concession located in an extremely prospective basin.”

Consulting Agreement with Hydrocarb

In conjunction with the closing of the Acquisition, Duma entered into a Consulting Services Agreement with Hydrocarb (the “Consulting Agreement”) whereby Hydrocarb will provide various consulting services with respect to Duma’s business ventures in Namibia and Hydrocarb acknowledges and agrees that the obligations of NEI under the Farm-in Opportunity Report between NEI and Hydrocarb (the “FOR”) will be satisfied in exchange for Duma paying a consulting fee (the “Fee”) to Hydrocarb of $2,400,000, payable over a 2 year period using either cash or restricted common shares of Duma.

Further information regarding the Acquisition, the Consulting Agreement, or the concession in Namibia may be found at the Company’s website at www.duma.com or by viewing the Company’s recent SEC filings.

About Duma Energy Corp.

Duma Energy Corp. (DUMA) is an aggressive growth company actively producing oil and gas in the continental United States, both on and offshore. Duma also has a significant interest in a 5.3-million acre concession in the Republic of Namibia in Southern Africa. Duma Energy will continue increasing revenue, cash flow, and reserves while pursuing aggressive growth through acquisition and participation in projects with the potential of providing exponential returns for shareholders. Further information can be found on the Company’s website at www.duma.com.

About Hydrocarb Corporation

Hydrocarb Corporation is a privately held energy exploration and production company targeting major under-explored oil and gas projects in emerging, highly prospective regions of the world. With headquarters in Houston, Texas, Hydrocarb maintains offices in Abu Dhabi, UAE and Windhoek, Namibia. For further information: www.hydrocarb.com

Safe Harbor Statements

Except for the statements of historical fact contained herein, the information presented in this news release constitutes “forward-looking statements” as such term is used in applicable United States laws. These statements relate to analyses and other information that are based on forecasts of future results, estimates of amounts not yet determinable and assumptions of management. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions or future events or performance (often, but not always, using words or phrases such as “expects” or “does not expect”, “is expected”, “anticipates” or “does not anticipate”, “plans, “estimates” or “intends”, or stating that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved) are not statements of historical fact and should be viewed as “forward-looking statements”. Such forward looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Such risks and other factors include, among others, the actual results of exploration activities, variations in the underlying assumptions associated with the estimation or realization of oil or gas resources, the availability of capital to fund programs and the resulting dilution caused by the raising of capital through the sale of shares, accidents, labour disputes and other risks of the oil and gas industry including, without limitation, those associated with the environment, delays in obtaining governmental approvals, permits or financing or in the completion of development or construction activities, title disputes or claims limitations on insurance coverage. Although the Company has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other factors that cause actions, events or results not to be as anticipated, estimated or intended. There can be no assurance that such statements will prove to be accurate as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements contained in this news release and in any document referred to in this news release.

Forward looking statements are made based on management’s beliefs, estimates and opinions on the date the statements are made and the Company undertakes no obligation to update forward-looking statements if these beliefs, estimates and opinions or other circumstances should change, except as required by applicable law. Such forward-looking statements reflect our current views with respect to future events and are subject to certain risks, uncertainties and assumptions, including, the risks and uncertainties outlined in our most recent financial statements and reports and registration statement filed with the United States Securities and Exchange Commission (the “SEC”) (available at www.sec.gov). Such risks and uncertainties may include, but are not limited to, the risks and uncertainties set forth in the Company’s filings with the SEC, such as the ability to obtain additional financing, the effect of economic and business conditions, the ability to attract and retain skilled personnel and factors outside the control of the Company. These forward-looking statements are made as of the date of this news release, and the Company assumes no obligation to update the forward-looking statements or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although the Company believes that the beliefs, plans, expectations and intentions contained in this news release are reasonable, there can be no assurance those beliefs, plans, expectations or intentions will prove to be accurate. Investors should consider all of the information set forth herein and should also refer to the risk factors disclosed in the Company’s periodic reports filed from time-to-time with the SEC.

This news release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction.

CONTACT: Investor Relations
Investor Awareness, Inc.
Tony Schor, 847-945-2222
www.InvestorAwareness.com

GlobalWise (GWIV) 8-K and Entry into a Material Definitive Agreement

Entry into a Material Definitive Agreement, Creation of a Direct Finan

Item 1.01. Entry into a Material Definitive Agreement.

On August 16, 2012, Intellinetics, Inc. (“Intellinetics”), the operating subsidiary of Globalwise Investments, Inc. and Alpharion Capital Partners (“Alpharion”) entered into a promissory note combination #1 agreement dated August 16, 2012, (the “Note Combination #1”) combining Alpharion Note #2, Alpharion Note #5, Alpharion Note #9, Alpharion Note #10, and Alpharion Note #11, (all such notes are hereinafter defined) with an aggregate principal amount of $118,556.39 and extending the due date of all such notes until September 30, 2012, without changing any other terms, The Note Combination #1 is filed as Exhibit 10.1 to this Current Report on Form 8-K. The summary of the terms of the Note Combination #1 contained herein is qualified in its entirety by reference such Exhibit 10.1.

On October 7, 2011, Intellinetics and Alpharion entered into a promissory note and subscription agreement dated October 7, 2011, in the principal amount of $7,500, at an interest rate of 3.25% (the “Alpharion Note #2”). The Alpharion Note #2 was due one hundred and eighty days from October 7, 2011. All past-due principal and accrued and past-due interest on the Alpharion Note #1 shall bear interest until paid at the rate of 3.25%. Pursuant to the Alpharion Note #2, the Company made certain customary representations, warranties and covenants. Payment of indebtedness under the Alpharion Note #2 may be accelerated upon a default in payment or in any of the terms, covenants, agreements, conditions or provisions of the Alpharion Note #2, if not cured pursuant to the terms therein, or in the event of any insolvency or bankruptcy of Intellinetics. The Alpharion Note #2 is filed as Exhibit 10.2 to this Current Report on Form 8-K. The summary of the terms of the Alpharion Note #2 contained herein is qualified in its entirety by reference such Exhibit 10.2.

On March 4, 2012, Intellinetics and Alpharion entered into a promissory note extension agreement dated March 4, 2012 (the “March 4, 2012 Extension Agreement”) extending the Alpharion Note #2 to a due date that is two hundred and seventy days from the October 7, 2011. All other provisions of Alpharion Note #2 were unchanged. The March 4, 2012 Extension Agreement is filed as Exhibit 10.3 to this Current Report on Form 8-K. The summary of the terms of the March 4, 2012 Extension Agreement contained herein is qualified in its entirety by reference such Exhibit 10.3.

On July 2, 2012, Intellinetics and Alpharion entered into a promissory note second extension agreement dated July 2, 2012 (the “July 2, 2012 Second Extension Agreement”) extending the Alpharion Note #2 to a due date that is three hundred fifteen days from the October 7, 2011. All other provisions of Alpharion Note #2 were unchanged. The July 2, 2012 Second Extension Agreement is filed as Exhibit 10.4 to this Current Report on Form 8-K. The summary of the terms of the July 2, 2012 Second Extension Agreement contained herein is qualified in its entirety by reference such Exhibit 10.4.

On November 21, 2011, Intellinetics and Alpharion entered into a promissory note and subscription agreement dated November 21, 2011, in the principal amount of $37,500, at an interest rate of 3.25% (the “Alpharion Note #5”). The Alpharion Note #5 was due one hundred and eighty days from November 21, 2011. All past-due principal and accrued and past-due interest on the Alpharion Note #5 shall bear interest until paid at the rate of 3.25%. Pursuant to the Alpharion Note #5, the Company made certain customary representations, warranties and covenants. Payment of indebtedness under the Alpharion Note #5 may be accelerated upon a default in payment or in any of the terms, covenants, agreements, conditions or provisions of the Alpharion Note #5, if not cured pursuant to the terms therein, or in the event of any insolvency or bankruptcy of Intellinetics. The Alpharion Note #5 is filed as Exhibit 10.5 to this Current Report on Form 8-K. The summary of the terms of the Alpharion Note #5 contained herein is qualified in its entirety by reference such Exhibit 10.5.

On May 13, 2012, Intellinetics and Alpharion entered into a promissory note extension agreement dated May 13,, 2012 (the “May 13, 2012 Extension Agreement”) extending the Alpharion Note #5 to a due date that is two hundred and seventy days from the November 21, 2011. All other provisions of Alpharion Note #5 were unchanged. The May 13, 2012 Extension Agreement is filed as Exhibit 10.6 to this Current Report on Form 8-K. The summary of the terms of the May 13, 2012 Extension Agreement contained herein is qualified in its entirety by reference such Exhibit 10.6.

On January 4, 2012, Intellinetics and Alpharion entered into a promissory note and subscription agreement dated January 4, 2012, in the principal amount of $13,556.39, at an interest rate of 3.25% (the “Alpharion Note #9”). The Alpharion Note #9 was due one hundred and eighty days from January 4, 2012. All past-due principal and accrued and past-due interest on the Alpharion Note #9 shall bear interest until paid at the rate of 3.25%. Pursuant to the Alpharion Note #9, the Company made certain customary representations, warranties and covenants. Payment of indebtedness under the Alpharion Note #9 may be accelerated upon a default in payment or in any of the terms, covenants, agreements, conditions or provisions of the Alpharion Note #9, if not cured pursuant to the terms therein, or in the event of any insolvency or bankruptcy of Intellinetics. The Alpharion Note #9 is filed as Exhibit 10.7 to this Current Report on Form 8-K. The summary of the terms of the Alpharion Note #9 contained herein is qualified in its entirety by reference such Exhibit 10.7.

On July 1, 2012, Intellinetics and Alpharion entered into a promissory note extension agreement dated July 1, 2012 (the “July 1, 2012 Extension Agreement”) extending the Alpharion Note #9 to a due date that is two hundred and twenty five days from the January 4, 2011. All other provisions of Alpharion Note #9 were unchanged. The July 1, 2012 Extension Agreement is filed as Exhibit 10.8 to this Current Report on Form 8-K. The summary of the terms of the July 1, 2012 Extension Agreement contained herein is qualified in its entirety by reference such Exhibit 10.8.

On January 9, 2012, Intellinetics and Alpharion entered into a promissory note and subscription agreement dated January 9, 2012, in the principal amount of $10,000, at an interest rate of 3.25% (the “Alpharion Note #10”). The Alpharion Note #10 was due one hundred and eighty days from January 9, 2012. All past-due principal and accrued and past-due interest on the Alpharion Note #10 shall bear interest until paid at the rate of 3.25%. Pursuant to the Alpharion Note #10, the Company made certain customary representations, warranties and covenants. Payment of indebtedness under the Alpharion Note #10 may be accelerated upon a default in payment or in any of the terms, covenants, agreements, conditions or provisions of the Alpharion Note #10, if not cured pursuant to the terms therein, or in the event of any insolvency or bankruptcy of Intellinetics. The Alpharion Note #10 is filed as Exhibit 10.9 to this Current Report on Form 8-K. The summary of the terms of the Alpharion Note #9 contained herein is qualified in its entirety by reference such Exhibit 10.9.

On July 6, 2012, Intellinetics and Alpharion entered into a promissory note extension agreement dated July 6, 2012 (the “July 6, 2012 Extension Agreement”) extending the Alpharion Note #10 to a due date that is two hundred and twenty five days from the January 6, 2011. All other provisions of Alpharion Note #10 were unchanged. The July 6, 2012 Extension Agreement is filed as Exhibit 10.10 to this Current Report on Form 8-K. The summary of the terms of the July 6, 2012 Extension Agreement contained herein is qualified in its entirety by reference such Exhibit 10.10.

On January 19, 2012, Intellinetics and Alpharion entered into a promissory note and subscription agreement dated January 19, 2012, in the principal amount of $50,000, at an interest rate of 3.25% (the “Alpharion Note #11”). The Alpharion Note #11 was due one hundred and eighty days from January 19, 2012. All past-due principal and accrued and past-due interest on the Alpharion Note #11 shall bear interest until paid at the rate of 3.25%. Pursuant to the Alpharion Note #10, the Company made certain customary representations, warranties and covenants. Payment of indebtedness under the Alpharion Note #11 may be accelerated upon a default in payment or in any of the terms, covenants, agreements, conditions or provisions of the Alpharion Note #11, if not cured pursuant to the terms therein, or in the event of any insolvency or bankruptcy of Intellinetics. The Alpharion Note #11 is filed as Exhibit 10.11 to this Current Report on Form 8-K. The summary of the terms of the Alpharion Note #9 contained herein is qualified in its entirety by reference such Exhibit 10.11.

On July 16, 2012, Intellinetics and Alpharion entered into a promissory note extension agreement dated July 16, 2012 (the “July 16, 2012 Extension Agreement”) extending the Alpharion Note #11 to a due date that is two hundred and twenty five days from the January 16, 2011. All other provisions of Alpharion Note #11 were unchanged. The July 16, 2012 Extension Agreement is filed as Exhibit 10.12 to this Current Report on Form 8-K. The summary of the . . .

Item 2.03. Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant.

On August 16, 2012, Intellinetics and Alpharion entered into the Note Combination #1. The terms of the Note Combination #1 are described in Item 1.01 of this Current Report on Form 8-K, which description is incorporated herein by reference.

On September 2, 2012, Intellinetics and Alpharion entered into the Note Combination #2. The terms of the Note Combination #2 are described in Item 1.01 of this Current Report on Form 8-K, which description is incorporated herein by reference.

On September 2, 2012, Intellinetics and Alpharion entered into the Note Combination #3. The terms of the Note Combination #3 are described in Item 1.01 of this Current Report on Form 8-K, which description is incorporated herein by reference.

On September 2, 2012, Intellinetics and Alpharion entered into the Note Combination #4. The terms of the Note Combination #4 are described in Item 1.01 of this Current Report on Form 8-K, which description is incorporated herein by reference.

On September 2, 2012, Intellinetics and Alpharion entered into the Note Combination #5. The terms of the Note Combination #5 are described in Item 1.01 of this Current Report on Form 8-K, which description is incorporated herein by reference.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

Exhibit No. Name of Exhibit

10.1* Promissory note combination #1 agreement dated August 16, 2012, by and
among Intellinetics and Alpharion combining Alpharion Note #2, Alpharion
Note #5, Alpharion Note #9, Alpharion Note #10, and Alpharion Note #11,
with an aggregate principal amount of $118,556.39 and extending the due
date of all such notes until September 30, 2012.
10.2* Promissory note and subscription agreement dated October 7, 2011, by and
among Intellinetics and Alpharion in the principal amount of $7,500.
10.3* Promissory note extension agreement dated March 4, 2012 by and among
Intellinetics and Alpharion.
10.4* Promissory note second extension agreement dated July 2, 2012 by and
among Intellinetics and Alpharion.
10.5* Promissory note and subscription agreement dated November 21, 2011, by
and among Intellinetics and Alpharion in the principal amount of
$37,500.
10.6* Promissory note extension agreement dated May 13,, 2012 by and among
Intellinetics and Alpharion.
10.7* Promissory note and subscription agreement dated January 4, 2012, by and
among Intellinetics and Alpharion in the principal amount of
$13,556.39.
10.8* Promissory note extension agreement dated July 1, 2012 by and among
Intellinetics and Alpharion.
10.9* Promissory note and subscription agreement dated January 9, 2012, by
and among Intellinetics and Alpharion in the principal amount of
$10,000, at an interest rate of 3.25%.
10.10* Promissory note extension agreement dated July 6, 2012 by and among
Intellinetics and Alpharion.
10.11* Promissory note and subscription agreement dated January 19, 2012, by
and among Intellinetics and Alpharion in the principal amount of
$50,000.
10.12* Promissory note extension agreement dated July 16, 2012 by and among
Intellinetics and Alpharion.
10.13* Promissory note combination #2 agreement dated September 2, 2012, (the
“Note Combination #2”) by and among Intellinetics and Alpharion
combining Alpharion Note #1, Alpharion Note #3, Alpharion Note #7, and
Alpharion Note #15 with an aggregate principal amount of $115,000 and
extending the due date of all such notes until November 16, 2012.
10.14* Promissory note and subscription agreement dated September 8, 2011, in
the principal amount of $17,500, by and among Intellinetics and
Alpharion.
10.15* Promissory note extension agreement dated March 6, 2012 by and among
Intellinetics and Alpharion.
10.16* Promissory note and subscription agreement dated November 1, 2011, in
the principal amount of $7,500,. by and among Intellinetics and
Alpharion
10.17* Promissory note extension agreement dated May 7, 2012 by and among
Intellinetics and Alpharion.
10.18* Promissory note second extension agreement dated July 27, 2012 by and
among Intellinetics and Alpharion.
10.19* Promissory note and subscription agreement dated December 7, 2011, in
the principal amount of $80,000, by and among Intellinetics and
Alpharion.
10.20* Promissory note extension agreement dated June 4, 2012 by and among
Intellinetics and Alpharion.
10.21* Promissory note and subscription agreement dated February 14, 2012, in
the principal amount of $10,000, by and among Intellinetics and
Alpharion.
10.22* Promissory note extension agreement dated August 11, 2012 by and among
Intellinetics and Alpharion.
10.23* Promissory note combination #3 agreement dated September 2, 2012, (the
“Note Combination #3”) by and among Intellinetics and Alpharion
combining Alpharion Note #8, Alpharion Note #18, with an aggregate
principal amount of $119,000 and extending the due date of all such
notes until November 16, 2012.
10.24* Promissory note and subscription agreement dated December 9, 2011, in
the principal amount of $15,000, by and among Intellinetics and
Alpharion.
10.25* Promissory note extension agreement dated June 6, 2012 by and among
Intellinetics and Alpharion.
10.26* Promissory note and subscription agreement dated March 9, 2012, in the
principal amount of $104,000, by and among Intellinetics and Alpharion.
10.27* Promissory note combination #4 agreement dated September 2, 2012, (the
“Note Combination #4”) by and among Intellinetics and Alpharion
combining Alpharion Note #12, Alpharion Note #14, Alpharion Note #19,
and Alpharion Note #20 with an aggregate principal amount of $111,500.
10.28* Promissory note and subscription agreement dated January 27, 2012, in
the principal amount of $5,000, by and among Intellinetics and
Alpharion.

10.29* Promissory note extension agreement dated July 24, 2012 by and among
Intellinetics and Alpharion.
10.30* Promissory note and subscription agreement dated February 10, 2012, in
the principal amount of $85,000,. by and among Intellinetics and
Alpharion.
10.31* Promissory note extension agreement dated July 24, 2012 by and among
Intellinetics and Alpharion.
10.32* Promissory note and subscription agreement dated March 14, 2011, in the
principal amount of $15,000, by and among Intellinetics and Alpharion.
10.33* Promissory note and subscription agreement dated March 15, 2011, in the
principal amount of $6,500, by and among Intellinetics and Alpharion.
10.34* Promissory note combination #5 agreement dated September 2, 2012, by and
among Intellinetics and Alpharion.
10.35* Promissory note and subscription agreement dated January 31, 2012, in
the principal amount of $35,000, by and among Intellinetics and
Alpharion.
10.36* Promissory note extension agreement dated July 28, 2012 by and among
Intellinetics and Alpharion.
10.37* Promissory note and subscription agreement dated February 15, 2012, by
and among Intellinetics and Alpharion.
10.38* Promissory note extension agreement dated August 12, 2012 by and among
Intellinetics and Alpharion.

VistaGen Therapeutics (VSTA) Announces Strategic Financing With Platinum Long Term Growth Fund

SOUTH SAN FRANCISCO, CA — (Marketwire) — 09/06/12 — VistaGen Therapeutics, Inc. (OTCBB: VSTA) (OTCQB: VSTA), a biotechnology company applying stem cell technology for drug rescue and novel pharmaceutical assays for predictive heart and liver toxicology and drug metabolism screening, today announced that Platinum Long Term Growth VII, LLC (Platinum) purchased a $750,000 secured convertible promissory note from the Company, supplementing its purchase in July 2012 of a similar note in the principal amount of $500,000. VistaGen currently anticipates that all amounts due under the two notes will be rolled into a proposed financing by Platinum expected to result in gross proceeds to VistaGen of at least $3.25 million, including $1.25 million from the two outstanding notes.

In addition, VistaGen announced the strategic restructuring of approximately $2.38 million of long-term indebtedness to Morrison & Foerster LLP (M&F), its intellectual property counsel. The restructuring is expected to result in VistaGen’s issuance of restricted common stock to M&F, at a price of $1.00 per share, as payment for approximately $1.38 million of the principal amount of such long-term indebtedness.

“We are very pleased with these recent endorsements from our largest institutional investor and our highly-regarded, long-time intellectual property counsel,” stated Shawn K. Singh, CEO of VistaGen Therapeutics. “Their confidence in our team and stem cell technology platform is a key component of the foundation underlying our core drug rescue, predictive toxicology and drug metabolism screening initiatives.”

Further information regarding VistaGen’s recent financing and debt restructuring transactions with Platinum Long Term Growth Fund and Morrison & Foerster, respectively, is set forth in the Company’s Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission (SEC) and available on both the SEC’s website at www.sec.gov and the Company’s website at www.VistaGen.com.

About VistaGen Therapeutics

VistaGen is a biotechnology company applying human pluripotent stem cell technology for drug rescue and novel pharmaceutical assays for predictive heart and liver toxicology and drug metabolism screening. VistaGen’s drug rescue activities are focused on combining its human pluripotent stem cell technology platform, Human Clinical Trials in a Test Tube™, with modern medicinal chemistry to generate new chemical variants (Drug Rescue Variants) of once-promising small-molecule drug candidates. These are drug candidates discontinued due to heart or liver toxicity after substantial development by large pharmaceutical companies, the U.S. National Institutes of Health (NIH) or university laboratories. VistaGen uses its pluripotent stem cell technology to generate early indications, or predictions, of how humans will ultimately respond to new drug candidates before they are ever tested in humans, bringing human biology to the front end of the drug development process.

Additionally, VistaGen’s orally-available, small molecule drug candidate, AV-101, is completing Phase 1b development for treatment of neuropathic pain. Neuropathic pain, a serious and chronic condition causing pain after an injury or disease of the peripheral or central nervous system, affects approximately 1.8 million people in the U.S. alone. VistaGen is currently exploring strategic partnering opportunities to leverage its current Phase 1 clinical program and enable Phase 2 clinical development of AV-101 for neuropathic pain, depression and potentially other neurological diseases or conditions. To date, VistaGen has been awarded over $8.5 million from the NIH for development of AV-101.

Visit VistaGen at http://www.VistaGen.com, follow VistaGen at http://www.twitter.com/VistaGen or view VistaGen’s Facebook page at http://www.facebook.com/VistaGen.

Cautionary Statement Regarding Forward-Looking Statements
The statements in this press release that are not historical facts may constitute forward-looking statements that are based on current expectations and are subject to risks and uncertainties that could cause actual future results to differ materially from those expressed or implied by such statements. Those risks and uncertainties include, but are not limited to, risks related to the successful completion of the Company’s ongoing clinical studies involving AV-101, the failure of the Company’s future drug rescue programs involving its stem cell technology-based Human Clinical Trial in a Test Tube™ platform, the Company’s ability to enter into third-party drug rescue collaborations, risks and uncertainties relating to the availability of substantial additional capital from Platinum or any other investor to support the Company’s research, development and commercialization activities, and the success of its research and development plans and strategies, including plans and strategies related to AV-101 and any drug rescue variant identified and developed by VistaGen. These and other risks and uncertainties are identified and described in more detail in VistaGen’s filings with the Securities and Exchange Commission (SEC). These filings are available on the SEC’s website at www.sec.gov. VistaGen undertakes no obligation to publicly update or revise any forward-looking statements.

For More Information:
Shawn K. Singh, J.D.
Chief Executive Officer
VistaGen Therapeutics, Inc.
www.VistaGen.com
650-244-9990 x224
Investor.Relations@VistaGen.com

Mission Investor Relations
Atlanta, Georgia
http://www.MissionIR.com
404-941-8975
Investors@MissionIR.com

Orexigen Therapeutics (OREX) announces continued rapid enrollment into the Light Study

SAN DIEGO, Sept. 5, 2012 /PRNewswire/ — Orexigen® Therapeutics, Inc. (Nasdaq: OREX) today announced an update to the projected timeframe for enrollment of patients in the Light Study, the cardiovascular outcomes clinical trial evaluating Contrave® (naltrexone SR/ bupropion SR). Enrollment into the study has continued without abatement at a rate faster than originally expected, with more than 4,500 patients enrolled as of August 31. Orexigen now expects to close enrollment to new patients in the fourth quarter of 2012.

The primary endpoint of the Light Study is the time to occurrence of major adverse cardiovascular events (MACE) during randomized treatment for Contrave compared to placebo. After at least 87 MACE have been adjudicated, the study’s independent Data Monitoring Committee will conduct an interim analysis. If the interim analysis excludes a doubling of risk of MACE in patients receiving Contrave compared to placebo, Orexigen plans to resubmit the Contrave New Drug Application (NDA) to the United States Food and Drug Administration (FDA) for approval. The exclusion of a doubling of risk of MACE was established as the threshold for approvability of Contrave during discussions with the FDA prior to the start of the Light Study.

“By successfully expediting patient enrollment into the Light Study, we are executing on our promise to shareholders to do what we can to pull forward the time to the interim analysis,” said Michael Narachi, CEO of Orexigen.

“The other key information needed to determine the timing of the interim analysis is the rate of MACE in the study, which is still too early to know,” Narachi continued. “Importantly, because the demographics of the patient population entering the study are in line with our targets for age, gender, race, smoking status, prevalence of cardiovascular disease and other co-morbidities, we remain confident that we will have the requisite number of events needed to conduct the interim analysis in 2013. We would expect to update investors with a more precise estimate of the timing of the interim analysis after we have received sufficient information about the rate of events from the Data Monitoring Committee.”

As a result of the successful acceleration of enrollment, some expenses associated with the Light Study will shift from 2013 into 2012. Accelerating enrollment does not result in a change to the Company’s guidance that current cash, cash equivalents and marketable securities will last through the anticipated timing of the resubmission of the Contrave NDA.

About Orexigen Therapeutics

Orexigen Therapeutics, Inc. is a biopharmaceutical company focused on the treatment of obesity. The Company’s lead product candidate is Contrave, which has completed Phase III clinical trials and for which a New Drug Application has been submitted and reviewed by the FDA. The Company has also reached agreement with the FDA on a Special Protocol Assessment (SPA) for the Light Study, the Contrave cardiovascular outcomes trial. The Company’s other product candidate, Empatic™, has completed Phase II clinical trials. Further information about the Company can be found at www.orexigen.com.

Forward-Looking Statements

Orexigen cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements. Words such as “believes,” “anticipates,” “plans,” “expects,” “indicates,” “will,” “intends,” “potential,” “suggests,” “assuming,” “designed” and similar expressions are intended to identify forward-looking statements. These statements are based on the Company’s current beliefs and expectations. These forward-looking statements include statements regarding the timing of patient enrollment and MACE events in the Light Study; the ability to enroll the targeted patient population; the ability to activate sites and conduct the Light Study; the potential for, and timing of, the accrual and adjudication of MACE events and the potential resubmission of the Contrave NDA; the safety and effectiveness of Contrave; the potential for, and timing of, approval for Contrave and that the Company’s cash, cash equivalents and marketable securities will last through the anticipated timing of the resubmission of the Contrave NDA. The inclusion of forward-looking statements should not be regarded as a representation by Orexigen that any of its plans will be achieved. Actual results may differ from those set forth in this release due to the risk and uncertainties inherent in the Orexigen business, including, without limitation: the Special Protocol Assessment (SPA) is not binding on the FDA if public health concerns unrecognized at the time the SPA agreement was entered into become evident, other new scientific concerns regarding product safety or efficacy arise, or if Orexigen fails to comply with the agreed upon trial protocol; Orexigen’s ability to conduct the Light Study and the progress and timing thereof, including risks associated with recruiting and enrolling patients in the Light Study; Orexigen’s ability to demonstrate in the Light Study that the risk of MACE in overweight and obese subjects treated with Contrave does not adversely affect the product candidate’s benefit-risk profile; the potential that earlier clinical trials may not be predictive of future results in the Light Study; the potential for the FDA to not approve Contrave even after the resubmission with the MACE event data; the potential for the Light Study to cost more than what is projected; the potential for early termination of the collaboration agreement between Orexigen and Takeda; the costs and time required to complete additional clinical, non-clinical or other requirements prior to any resubmission of an NDA; the therapeutic and commercial value of Contrave; Orexigen’s ability to maintain sufficient capital; and other risks described in the Company’s filings with the Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and Orexigen undertakes no obligation to revise or update this news release to reflect events or circumstances after the date hereof. Further information regarding these and other risks is included under the heading “Risk Factors” in Orexigen’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission August 9, 2012 and which is available from the SEC’s website (www.sec.gov) and on Orexigen’s website (www.orexigen.com) under the heading “Investor Relations.” All forward-looking statements are qualified in their entirety by this cautionary statement. This caution is made under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995.

Orexigen Contact:

Media Contact:

McDavid Stilwell

Denise Powell

VP, Corporate Communications and Business Development

WCG

(858) 875-8629

(510) 703-9491

Gold Standard (GSV) Announces Appointment of New Independent Director

VANCOUVER, BRITISH COLUMBIA — (Marketwire) — 09/05/12 — Gold Standard Ventures Corp. (TSX VENTURE:GSV)(NYSE MKT:GSV)(NYSE Amex:GSV) (“Gold Standard” or the “Company”) (www.goldstandardv.com) has appointed Jamie Strauss to its Board as an independent director.

Mr. Strauss is currently a Director of a boutique mining finance firm, Strauss Partners, based in London, England. Jamie has worked as a stockbroker in the City of London for 25 years, specialising in the corporate resource arena, including a term as Managing Director of UK for BMO Capital Markets 2007-2009. He has raised in excess of $1bn in recent years for projects spanning the globe in both the energy and mineral world on behalf of leading institutions in North America, Australia and Europe. He has been a committee member of the Association of Mining Analysts for the last four years, and is a non-executive director of Wildhorse Energy Ltd. and Altius Minerals. Jamie was, until recently, a director of Extorre Gold Mines Ltd. until it was taken over by Yamana.

“Mr. Strauss brings over 25 years of mining sector experience in capital markets and should help strengthen Gold Standard’s presence in Europe. We are extremely pleased to welcome him to our Board,” said Jonathan Awde, a director and chief executive officer of Gold Standard Ventures.

The Company also announces that, pursuant to its stock option incentive plan, it has granted director incentive stock options to purchase 150,000 common shares of the company at today’s closing price for a period of 5 years.

The stock options are subject to the terms of the Company’s stock option plan and regulatory approval.

ABOUT GOLD STANDARD VENTURES – Gold Standard is a Canadian-based company focused on the acquisition and exploration of district-scale and other gold-bearing mineral properties exclusively in the State of Nevada, United States. The Company’s flagship property is the Railroad Project, located in Elko County, Nevada. The Railroad Project is a prospective gold exploration target comprising approximately 19,764 acres (30.8 square miles) within the Carlin Trend of north-central Nevada.

On behalf of the Board of Directors of Gold Standard,

Jonathan Awde, President and Director

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

This news release contains forward-looking statements, which relate to future events or future performance and reflect management’s current expectations and assumptions. Such forward-looking statements reflect management’s current beliefs and are based on assumptions made by and information currently available to the Company. All statements, other than statements of historical fact, included herein including, without limitation, statements about the intended use of proceeds from the Offering are forward looking statements. By their nature, forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements, or other future events, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors include, among others, the following risks: operational risks associated with mineral exploration; fluctuations in commodity prices; title matters; and the additional risks identified in our filings with Canadian securities regulators on SEDAR in Canada (available at www.sedar.com) and with the SEC on EDGAR (available at www.sec.gov/edgar.shtml). These forward-looking statements are made as of the date hereof and, except as required under applicable securities legislation, the Company does not assume any obligation to update or revise them to reflect new events or circumstances.

Neither the TSXV nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) nor the NYSE MKT accepts responsibility for the adequacy or accuracy of this news release.

Contacts:
Gold Standard Ventures Corp.
Jonathan Awde
President
604-669-5702
info@goldstandardv.com
www.goldstandardv.com

Progenitor (NBS) a NeoStem Company, Invited to Present at Two Conferences

NEW YORK, Sept. 5, 2012 (GLOBE NEWSWIRE) — NeoStem, Inc. (NYSE:NBS) (“NeoStem” or the “Company”), a cell therapy company, today announced that Company management of a NeoStem company, Progenitor Cell Therapy (“PCT”), an internationally recognized contract development and manufacturing organization (CDMO), has been invited to present on its core expertise in development of commercial manufacturing processes for cell therapy at two cell therapy conferences in September. At each, PCT will offer its unique perspective as an industry leader in contract development and manufacturing of cell therapy products, with over 12 years of exclusive cell-therapy focused experience.

Timothy Fong, Ph.D, M.B.A, PCT’s Vice President, Technology and Product Development, will be sharing PCT’s expertise in cell therapy manufacturing with a focus on commercialization. At IBC Life Sciences’ Cell Therapy Bioprocessing Conference, he will chair a panel on quality assurance and controls and will give a presentation entitled “From Concept to Product: Considerations for Developing a Robust Commercial Manufacturing Process”, which will include considerations for developing a robust commercial manufacturing process. He will also speak at the Stem Cells USA and Regenerative Medicine Congress on “Cell manufacturing considerations for first-in-world stem cell therapeutics”.

Dr. Fong stated, “As a cell therapeutic progresses from concept to product, the development of a commercial manufacturing process may contain unexpected technical and quality issues. The development path should follow several defined steps. My presentations will discuss the key steps in the process and highlight critical areas that need to be addressed to develop a successful commercial manufacturing process. PCT helps clients bridge the gap between discovery and patient care through efficient transfer of cell-based therapies from laboratory into clinical practice.”

NeoStem and PCT invite you to attend the conference(s), see Dr. Fong’s talks, and connect with the PCT team at PCT’s booths. If you are a colleague of PCT or NeoStem, PCT can offer you a registration discount. Please contact PCT at bdm@pctcelltherapy.com for more details.

IBC Life Sciences’ 2nd Annual Cell Therapy Bioprocessing Conference

Date: September 12, 2012, 3:30 PM EDT
Venue: DoubleTree Crystal City Hotel, Arlington, VA
Presenter: Timothy Fong, Ph.D., M.B.A., PCT’s Vice President, Technology and Product Development

Terrapinn 4th Annual Stem Cells USA and Regenerative Medicine Congress

Date: September 21, 2012, 11:30 AM EDT
Venue: The Charles Hotel, Boston, MA
Presenter: Timothy Fong, Ph.D., M.B.A., PCT’s Vice President, Technology and Product Development

About NeoStem, Inc.

NeoStem, Inc. continues to develop and build on its core capabilities in cell therapy capitalizing on the paradigm shift that we see occurring in medicine. In particular, we anticipate that cell therapy will have a large role in the fight against chronic disease and in lessening the economic burden that these diseases pose to modern society. We are emerging as a technology and market leading company in this fast developing cell therapy market. Our multi-faceted business strategy combines a state-of-the-art contract development and manufacturing subsidiary, Progenitor Cell Therapy, LLC (“PCT”) with a medically important cell therapy product development program, enabling near and long-term revenue growth opportunities. We believe this expertise and existing research capabilities and collaborations will enable us to achieve our mission of becoming a premier cell therapy company.

Our contract development and manufacturing service business supports the development of proprietary cell therapy products. NeoStem’s most clinically advanced therapeutic, AMR-001, is being developed at Amorcyte, LLC (“Amorcyte”), which we acquired in October 2011. Amorcyte is developing a cell therapy for the treatment of cardiovascular disease and is enrolling patients in a Phase 2 trial to investigate AMR-001’s efficacy in preserving heart function after a heart attack. Athelos Corporation (“Athelos”), which is approximately 80%-owned by our subsidiary, PCT, is collaborating with Becton-Dickinson in the early clinical exploration of a T-cell therapy for autoimmune conditions. In addition, pre-clinical assets include our VSELTM Technology platform as well as our mesenchymal stem cells product candidate for regenerative medicine. Our service business and pipeline of proprietary cell therapy products work in concert, giving us a competitive advantage that we believe is unique to the biotechnology and pharmaceutical industries. Supported by an experienced scientific and business management team and a patent and patent pending (IP) portfolio, we believe we are well positioned to succeed.

For more information on NeoStem, please visit www.neostem.com. For more information on PCT, please visit www.pctcelltherapy.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect management’s current expectations, as of the date of this press release, and involve certain risks and uncertainties. Forward-looking statements include statements herein with respect to the successful execution of the Company’s business strategy, including with respect to the Company’s or its partners’ successful development of AMR-001 and other cell therapeutics, the size of the market for such products, its competitive position in such markets, the Company’s ability to successfully penetrate such markets and the market for its CDMO business, and the efficacy of protection from its patent portfolio, as well as the future of the cell therapeutics industry in general, including the rate at which such industry may grow. Forward looking statements also include statements with respect to satisfying all conditions to closing the disposition of Erye, including receipt of all necessary regulatory approvals in the PRC. The Company’s actual results could differ materially from those anticipated in these forward- looking statements as a result of various factors, including but not limited to (i) the Company’s ability to manage its business despite operating losses and cash outflows, (ii) its ability to obtain sufficient capital or strategic business arrangement to fund its operations, including the clinical trials for AMR-001, (iii) successful results of the Company’s clinical trials of AMR-001 and other cellular therapeutic products that may be pursued, (iv) demand for and market acceptance of AMR-001 or other cell therapies if clinical trials are successful and the Company is permitted to market such products, (v) establishment of a large global market for cellular-based products, (vi) the impact of competitive products and pricing, (vii) the impact of future scientific and medical developments, (viii) the Company’s ability to obtain appropriate governmental licenses and approvals and, in general, future actions of regulatory bodies, including the FDA and foreign counterparts, (ix) reimbursement and rebate policies of government agencies and private payers, (x) the Company’s ability to protect its intellectual property, (xi) the company’s ability to successfully divest its interest in Erye, and (xii) matters described under the “Risk Factors” in the Company’s Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 20, 2012 and in the Company’s other periodic filings with the Securities and Exchange Commission, all of which are available on its website. The Company does not undertake to update its forward-looking statements. The Company’s further development is highly dependent on future medical and research developments and market acceptance, which is outside its control.

CONTACT: Trout Group
Gitanjali Jain Ogawa, Vice President
Phone: +1-646-378-2949
Email: gogawa@troutgroup.com

TeleCommunication Systems (TSYS) Awardee on $2.6B Custom SATCOM Solutions IDIQ Contract

Department of Defense and Federal Civilian Agencies Now Able to Purchase End-to-End, Innovative Products, Services and Highly Reliable Connectivity

ANNAPOLIS, Md., Sept. 5, 2012 /PRNewswire/ — TeleCommunication Systems, Inc. (TCS) (NASDAQ: TSYS), a world leader in highly reliable and secure mobile communication technology, today announced it has been selected as one of eight awardees of the Custom SATCOM Solutions (CS2) contract. This contract enables the Department of Defense (DoD) and federal civilian agencies to purchase TCS end-to-end, turnkey solutions which incorporate commercial satellite communication services through both the General Services Administration (GSA) and the Defense Information Systems Agency (DISA). The multiple-awardee, Indefinite Delivery – Indefinite Quantity (IDIQ) contract, with an estimated ceiling of $2.6 billion over five years, is part of the Future Commercial Satellite Communications Services Acquisition (FCSA) strategy established by the GSA and DISA to consolidate transponded capacity (satellite bandwidth), subscription services (including terminal and bandwidth combinations) and end-to-end solutions contracting vehicles into one program for procuring custom satellite communication solutions from a select group of qualified contractors.

Government and defense organizations are increasing their reliance on commercial satellite technology to provide essential, secure communications to the warfighter, command and control functions, and disaster recovery and response teams. According to Northern Sky Research, the global market for commercial government satellite equipment and services will grow from $4 billion in 2011 to $9.2 billion in 2019. The need for flexible, mobile wireless services drives agencies toward industry leaders like TCS and its partners for state-of-the-art solutions to reliably and securely transmit voice, video and data across the globe. TCS has a 25-year history of providing proven, reliable and cost-effective secure communication solutions for all tiers of government, and this award will broaden access by government agencies to that experience.

Supporting Quote:

TCS Senior Vice President and General Manager of Government Solutions, Michael Bristol said, “This award significantly expands TCS access to business opportunities well-suited to TCS TotalCom solutions. For the next several years, CS2 will be the main contract vehicle for the DoD and federal civilian agencies to purchase commercial satcom solutions. This contract vehicle aligns perfectly with our business model. We are a value-added systems integrator that provides mission-critical Total Communication Solutions consisting of deployable satcom equipment, managed satcom network services and field support staff.”

For the past 25 years, TCS has established a proven track record as a trusted provider of communication technology solutions to solve the government’s toughest technical challenges, under conditions that demand the highest level of reliability, availability and security. To ensure mission continuity, TCS TotalCom™ offers deployable, highly secure communication solutions and complete end-to-end managed services for converged (IP-based) voice, video and data solutions to organizations requiring seamless and secure connectivity between fixed sites and remote operations.

About TeleCommunication Systems, Inc.

TeleCommunication Systems, Inc. (TCS) (NASDAQ: TSYS) is a world leader in highly reliable and secure mobile communication technology. TCS infrastructure forms the foundation for market leading solutions in E9-1-1, text messaging, commercial location and deployable wireless communications. TCS is at the forefront of new mobile cloud computing services providing wireless applications for navigation, hyper-local search, asset tracking, social applications and telematics. Millions of consumers around the world use TCS wireless apps as a fundamental part of their daily lives. Government agencies utilize TCS’ cyber security expertise, professional services, and highly secure deployable satellite solutions for mission-critical communications. Headquartered in Annapolis, MD, TCS maintains technical, service and sales offices around the world. To learn more about emerging and innovative wireless technologies, visit www.telecomsys.com.

Except for the historical information contained herein, this news release contains forward-looking statements as defined within Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities and Exchange Act of 1934, as amended. These statements are subject to risks and uncertainties and are based upon TCS’ current expectations and assumptions that if incorrect would cause actual results to differ materially from those anticipated. Risks include without limitation the possibility that TCS will not win task orders under the contract, that orders do not get fully funded, and those detailed from time to time in the Company’s SEC reports, including the reports on Form 10-K for the year ended December 31, 2011, and on Form 10-Q for the quarter ended June 30, 2012.

Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The Company undertakes no obligation to update or revise the information in this press release, whether as a result of new information, future events or circumstances, or otherwise.

(Logo: http://photos.prnewswire.com/prnh/20120503/PH99996LOGO )

Company Contact:

Media Contact:

Investor Relations:

TeleCommunication Systems, Inc.

Nadel Phelan, Inc.

Liolios Group, Inc.

Meredith Allen

Graham Sorkin

Scott Liolios

410-295-1865

831-440-2406

949-574-3860

MAllen@telecomsys.com

graham@nadelphelan.com

info@liolios.com

SOURCE TeleCommunication Systems, Inc.

SEFE (SEFE) CEO Don Johnston Featured on theStockRadio.com

BOULDER, CO — (Marketwire) — 09/05/12 — SEFE, Inc. (OTCBB: SEFE) (OTCQB: SEFE) (the “Company”), a sustainability company engaged in offering innovative, pioneering solutions for the world’s energy needs, today announced that theStockRadio.com has posted an audio interview recently conducted with Chief Executive Officer, Don Johnston.

To access the interview, visit http://thestockradio.com/donald-johnston-ceo-of-sefe-inc-otcsefe/1316.

Mr. Johnston introduced listeners to the company and reviewed its business strategy, technologies and patents, and current initiatives. He also discussed the science behind the Harmony III atmospheric energy system, progress with ongoing testing and development, and future plans.

About SEFE, Inc.

SEFE focuses on pushing the boundaries of what’s possible, embracing innovation and employing the cutting-edge to solve problems, and offering sustainable solutions to a world hungry for invention, direction and leadership. SEFE is technology- and solutions-driven, focusing on developing inventions that provide a real-world impact and true profitability. So, success is measured by both a sustainable return on investment, as well as a project’s sustainability from an environmental perspective.

For more information, visit www.SEFElectric.com.

About theStockRadio.com

theStockRadio.com, a small-cap research and investment commentary provider, strives to provide a balanced view of many promising small-cap companies that would otherwise fall under the radar of the typical Wall Street investor. Moreover, theStockRadio.com provides investors with an excellent first step in their research and due diligence by providing daily trading ideas, and consolidating the public information available on them.

For more information, visit www.thestockradio.com.

Forward-Looking Statements
This release, and the interview on theStockRadio.com referenced herein, include “forward-looking statements” as defined by the SEC. Any statements in this news release, referenced interviews and on our website and youtube page that are not historical facts are forward-looking statements that involve risks and uncertainties. Words such as “estimate,” “expect,” “would,” “target,” “goal,” “potential,” and forms of those words and others indicate forward-looking statements. These statements are based on certain assumptions made by the Company based on management’s experience and perception of historical trends, current conditions, anticipated future developments and other factors believed to be appropriate. Such statements are subject to a number of assumptions, risks and uncertainties, many of which are beyond the control of the Company, which may cause actual results to differ materially from those implied or expressed by the forward-looking statements. Further information on our business are discussed in the Company’s filings with the SEC, including its Annual Report on Form 10-K under the headings “Business” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations.” Our business is subject to various risks and uncertainties, including those described in our Registration Statement on Form 10 filed with the SEC, under the heading “Risk Factors.”

Contact:
SEFE, Inc.
Justin Ackerman
714-495-1927
ir@sefelectric.com

Mission Investor Relations
404-941-8975
Investors@MissionIR.com
www.MissionIR.com

Ocean Power Technologies (OPTT) to Work with U.S. Department of Homeland Security

Ocean Power Technologies to Work with U.S. Department of Homeland Security and Wins New Autonomous PowerBuoy Grant

Ocean Power Technologies, Inc. (Nasdaq: OPTT) (“OPT” or “the Company”) today announced that it has entered into a Cooperative Research and Development Agreement (“CRADA”) with the U.S. Department of Homeland Security (“DHS”) Science & Technology Directorate (“S&T”) to perform a new round of in-ocean tests on its Autonomous PowerBuoy® to further demonstrate its use for ocean surveillance.

Specifically, the DHS S&T Borders and Maritime Security Division will collaborate with OPT to demonstrate the effectiveness of its long duration maritime vessel detection platform. This will involve the redeployment of an APB-350 Autonomous PowerBuoy off the coast of New Jersey, where previous work through the U.S. Navy’s Littoral Expeditionary Autonomous PowerBuoy (“LEAP”) program last year produced extremely positive results, including higher-than-predicted power harvesting capability and survivability during Hurricane Irene and its 50-foot high waves.

In tandem with the CRADA, OPT has been awarded a new $75,000 grant from the Maryland Technology Development Corporation (“MTDC”) via a joint technology transfer initiative to show how the Autonomous PowerBuoy can be used with multiple surveillance technologies. OPT will leverage its experience from the LEAP program in surface vessel detection to demonstrate an enhanced tracking technology covering a wider variety of vessels. This technology will feature an acoustic sensor system in addition to the existing HF RADAR. This will allow the PowerBuoy to collect data for ocean observing applications at the same time as it performs its enhanced surveillance duties, demonstrating the dual use of the PowerBuoy technology.

“Building on our success in 2011 with the LEAP deployment, we are pleased to be implementing this advanced maritime security payload on our Autonomous PowerBuoy” said Charles F. Dunleavy, Chief Executive Officer of OPT. “The CRADA and the grant from the MTDC will assist us in the expansion of the Autonomous PowerBuoy capability for vessel detection operations, which is one of the significant potential markets for this product. We look forward to deploying the upgraded device.”

Autonomous PowerBuoys form an important part of OPT’s commercial product offering, and have been designed to generate power for off-grid applications such as offshore oil & gas installations, fish-farming as well as security and maritime monitoring. In February 2012, OPT reported results of the LEAP program under which its device supplied continuous power in excess of 400W throughout the entire deployment and produced peak sustained electrical power of 1,500W, easily exceeding the critical design goals.

About Ocean Power Technologies

Ocean Power Technologies, Inc. (Nasdaq: OPTT) is a pioneer in wave-energy technology that harnesses ocean wave resources to generate reliable and clean and environmentally-beneficial electricity. OPT has a strong track record in the advancement of wave energy and participates in an estimated $150 billion annual power generation equipment market. OPT’s proprietary PowerBuoy® system is based on modular, ocean-going buoys that capture and convert predictable wave energy into clean electricity. The Company is widely recognized as a leading developer of on-grid and autonomous wave-energy generation systems, benefiting from 15 years of in-ocean experience. OPT is headquartered in Pennington, New Jersey, USA with an office in Warwick, UK, and operations in Melbourne and Perth, Australia. More information can be found at www.oceanpowertechnologies.com.

Forward-Looking Statements

This release may contain “forward-looking statements” that are within the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements reflect the Company’s current expectations about its future plans and performance, including statements concerning the impact of marketing strategies, new product introductions and innovation, deliveries of product, sales, earnings and margins. These forward-looking statements rely on a number of assumptions and estimates which could be inaccurate and which are subject to risks and uncertainties. Actual results could vary materially from those anticipated or expressed in any forward-looking statement made by the Company. Please refer to the Company’s most recent Forms 10-Q and 10-K and subsequent filings with the SEC for a further discussion of these risks and uncertainties. The Company disclaims any obligation or intent to update the forward-looking statements in order to reflect events or circumstances after the date of this release.

**********

Peregrine (PPHM) to Report Q1 Data Early, Phase II Bavituximab Second-Line Lung Cancer Trial

Peregrine to Report First Quarter Fiscal Year 2013 Financial Results Before Market on September 10, 2012

TUSTIN, CA — (Marketwire) — 09/04/12 — Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM), a clinical-stage biopharmaceutical company developing first-in-class monoclonal antibodies focused on the treatment and diagnosis of cancer, today announced that it will report financial results for the first quarter of the fiscal year 2013 on September 10, 2012 before market and will host a conference call and webcast at 8:00 AM PDT (11:00 AM EDT). Peregrine’s senior management will discuss financial results for the first quarter of fiscal year ended July 30, 2012 and will review progress of its clinical development programs, including an overview of the bavituximab data that will be presented at the 2012 Chicago Multidisciplinary Symposium in Thoracic Oncology on September 7, 2012.

To listen to the live webcast, or access the archived webcast, please visit: http://ir.peregrineinc.com/events.cfm.

To listen to the conference call, please dial (877) 312-5443 or (253) 237-1126 and request the Peregrine Pharmaceuticals call. A replay of the call will be available starting approximately two hours after the conclusion of the call through September 24, 2012 by calling (855) 859-2056, or (404) 537-3406 and using passcode 27367274.

About Peregrine Pharmaceuticals

Peregrine Pharmaceuticals, Inc. is a biopharmaceutical company with a portfolio of innovative monoclonal antibodies in clinical trials focused on the treatment and diagnosis of cancer. The company is pursuing multiple clinical programs in cancer with its lead product candidate bavituximab and novel brain cancer agent Cotara®. Peregrine also has in-house cGMP manufacturing capabilities through its wholly-owned subsidiary Avid Bioservices, Inc. (www.avidbio.com), which provides development and biomanufacturing services for both Peregrine and outside customers. Additional information about Peregrine can be found at www.peregrineinc.com.

Add to Digg Bookmark with del.icio.us Add to Newsvine

Contact:
Christopher Keenan or Jay Carlson
Peregrine Pharmaceuticals
(800) 987-8256
info@peregrineinc.com

Data From Peregrine’s Phase II Bavituximab Second-Line Lung Cancer Trial to Be Highlighted in Late-Breaking Oral Presentation at the 2012 Chicago Multidisciplinary Symposium in Thoracic Oncology

TUSTIN, CA — (Marketwire) — 09/04/12 — Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM), a clinical-stage biopharmaceutical company developing first-in-class monoclonal antibodies focused on the treatment and diagnosis of cancer, today announced it will be presenting data from its double-blind, placebo controlled, Phase II bavituximab trial in second-line non-small cell lung cancer at an upcoming plenary presentation at the 2012 Chicago Multidisciplinary Symposium in Thoracic Oncology to be held at the Chicago Marriott Downtown Magnificent Mile in Chicago, Illinois from September 6-8, 2012. The late-breaking oral presentation will be held on September 7, 2012 at 1:40 PM CDT.

Oral Presentation Details:

Late-Breaking Plenary Presentation LBPL2

Title: Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial of Bavituximab Plus Docetaxel in Patients with Previously Treated Locally Advanced or Metastatic Non-Squamous Non-Small-Cell Lung Cancer (Top-line Results)

Speaker: David Gerber, M.D., University of Texas Southwestern Medical Center

Time: Friday, Sep 07, 2012, 1:40 PM – 1:50 PM CT

Authors: D. E. Gerber(1), M. Joppert(2), D. R. Spigel(3), D. P. Singh(4), D. Giorgadze(5), M. Shtivelband(6), O. V. Ponomarova(7), J. Shan(8), C. P. Belani(9)

1) Harold C. Simmons Cancer Center, University of Texas Southwestern Medical Center, Dallas, TX.; 2) Florida Cancer Specialists, Ft. Meyers, FL.; 3) Sarah Cannon Research Institute/Tennessee Oncology, PLLC, Nashville, TN.; 4) Department of Radiotherapy & Clinical Oncology, S.M.S. Medical College & Attached Hospitals, Jaipur, India.; 5) Chemotherapy and Immunotherapy Clinic, Tbilisi, Georgia.; 6) Ironwood Cancer and Research Centers, Chandler, AZ.; 7) RE Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology, Kiev, Ukraine.; 8) Peregrine Pharmaceuticals, Inc., Tustin, CA.; 9) Penn State Hershey Cancer Institute, Hershey, PA.

Audio Webcast
In conjunction with Dr. Gerber’s presentation in Chicago, Peregrine will post an audio webcast and slide deck to Peregrine’s website. The pre-recorded webcast will be hosted by Joseph Shan, vice president of clinical and regulatory affairs. Access to the audio and corresponding slides can be found on Peregrine’s website.

About Bavituximab
Bavituximab is a first-in-class phosphatidylserine (PS)-targeting monoclonal antibody that represents a new approach to treating cancer. Bavituximab is the lead drug candidate from the company’s PS technology platform and is currently being tested in eight clinical trials including three randomized Phase II trials in front-line and second-line non-small cell lung cancer, front-line pancreatic cancer and five investigator-sponsored trials (ISTs) in additional oncology indications and treatment combinations.

PS is a highly immunosuppressive molecule usually located inside the membrane of healthy cells, but “flips” and becomes exposed on the outside of cells that line tumor blood vessels, creating a specific target for anti-cancer treatments. PS-targeting antibodies target and bind to PS and block this immunosuppressive signal, thereby enabling the immune system to recognize and fight the tumor.

About Peregrine Pharmaceuticals
Peregrine Pharmaceuticals, Inc. is a biopharmaceutical company with a portfolio of innovative monoclonal antibodies in clinical trials focused on the treatment and diagnosis of cancer. The company is pursuing multiple clinical programs in oncology with its lead product candidate bavituximab and novel brain cancer agent Cotara®. Peregrine also has in-house cGMP manufacturing capabilities through its wholly-owned subsidiary Avid Bioservices, Inc. (www.avidbio.com), which provides development and biomanufacturing services for both Peregrine and outside customers. Additional information about Peregrine can be found at www.peregrineinc.com.

Add to Digg Bookmark with del.icio.us Add to Newsvine

Contact:
Christopher Keenan or Jay Carlson
Peregrine Pharmaceuticals
(800) 987-8256
info@peregrineinc.com

Dejour Energy (DEJ) Moves Drill Rig to Kokopelli Leasehold

Dejour Energy, Inc. (NYSE MKT: DEJ / TSX: DEJ) announces that a drill rig has been contracted to drill the first well at its 72% owned Kokopelli project in the Piceance Basin, Colorado and is in the process of moving onto the location. This well is expected to spud during the coming week and will be directionally drilled to the base of the Williams Fork, logged, with casing set during Q3 2012. Successful completion of this well will secure for Dejour the substantial portion of the proven and probable undeveloped reserves, ~200 BCFe including ~12MM barrels of liquids net to Dejour, attributed to the Williams Fork section of this Kokopelli leasehold by independent engineers. Production is expected to be tied into existing gathering systems in Q4 2012.

As previously reported this 2,200 acre project is ideally situated for exploitation of both the Williams Fork and Mancos hydrocarbon laden shale bodies immediately adjacent to Williams Energy (NYSE: WPX) and Bill Barrett Corporation (NYSE: BBG) who are developing and producing their respective leaseholds to the east, west and north of the Company’s acreage. Dejour USA has worked closely with important constituents including local citizenry and government, the Bureau of Land Management and the Colorado Division of Wildlife to develop a mutually acceptable development plan for this environmentally sensitive area. Construction of the first drilling pad commenced in the fourth quarter of 2011 with production expected to begin in the second half of 2012. According to National Instrument 51-101 standard in Canada, the reserves evaluation report for Dejour’s leases at Kokopelli Field effective December 31, 2011, performed by Gustavson and Associates of Boulder, Colorado, projects the before tax discounted net present value 10% (NPV10) of proved undeveloped (PUD) reserves valued at $94 million and proven plus probable undeveloped (2P) reserves valued at $202 million in the Williams Fork section net to Dejour, while the Mancos is felt to hold a resource of at least comparable value.

“We are pleased to commence drilling operations at Kokopelli and secure this valuable asset for the long-term. While the initial number of wells drilled has been reduced to reflect current commodity prices, we are committed to drill, complete and initiate production at Kokopelli, preserving significant value for all of our stakeholders,” stated Harrison Blacker, President and COO.

About Dejour

Dejour Energy Inc. is an independent oil and natural gas exploration and production company operating projects in North America’s Piceance Basin (approximately 100,000 net acres) and Peace River Arch regions (approximately 11,000 net acres). Dejour’s seasoned management team has consistently been among early identifiers of premium energy assets, repeatedly timing investments and transactions to realize their value to shareholders’ best advantage. Dejour maintains offices in Denver, USA, Calgary and Vancouver, Canada. The company is publicly traded on the New York Stock Exchange MKT (NYSE MKT: DEJ) and Toronto Stock Exchange (TSX: DEJ).

Statements Regarding Forward-Looking Information: This news release contains statements about oil and gas production and operating activities that may constitute “forward-looking statements” or “forward-looking information” within the meaning of applicable securities legislation as they involve the implied assessment that the resources described can be profitably produced in the future, based on certain estimates and assumptions. Forward-looking statements are based on current expectations, estimates and projections that involve a number of risks, uncertainties and other factors that could cause actual results to differ materially from those anticipated by Dejour and described in the forward-looking statements. These risks, uncertainties and other factors include, but are not limited to, the availability of funding for future projects, adverse general economic conditions, operating hazards, drilling risks, inherent uncertainties in interpreting engineering and geologic data, competition, reduced availability of drilling and other well services, fluctuations in oil and gas prices and prices for drilling and other well services, government regulation and foreign political risks, fluctuations in the exchange rate between Canadian and US dollars and other currencies, as well as other risks commonly associated with the exploration and development of oil and gas properties. Additional information on these and other factors, which could affect Dejour’s operations or financial results, are included in Dejour’s reports on file with Canadian and United States securities regulatory authorities. We assume no obligation to update forward-looking statements should circumstances or management’s estimates or opinions change unless otherwise required under securities law. The TSX does not accept responsibility for the adequacy or accuracy of this news release.

Follow Dejour Energy’s latest developments on:

Facebook http://facebook.com/dejourenergy and Twitter @dejourenergy

NTS Realty Holdings (NLP) Investigations

Holzer Holzer & Fistel, LLC Announces Investigation into the Going Private Transaction of NTS Realty Holdings LP

Holzer Holzer & Fistel, LLC is investigating whether the directors of NTS Realty Holdings LP (“NTS” or the “Company”) (NYSE: NLP) complied with their fiduciary duties in approving the proposed acquisition of the Company by its founder and Chairman, J.D. Nichols and its Chief Executive Officer, Brian F. Lavin. According to the Company’s announcement, if the deal closes NTS shareholders will receive $5.25 for each share of NLP owned. The firm’s investigation seeks to determine, among other things, whether the consideration to be paid to NTS shareholders is fair and adequate.

Current holders of NTS common stock with questions concerning their legal rights are encouraged to contact Holzer Holzer & Fistel, LLC and its attorneys Michael I. Fistel, Jr., Esq., or Marshall P. Dees, Esq. via email at mfistel@holzerlaw.com, or mdees@holzerlaw.com, or via toll-free telephone at (888) 508-6832.

Holzer Holzer & Fistel, LLC dedicates its practice to vigorous representation of shareholders and investors in litigation nationwide, including shareholder class action and derivative litigation. More information about the firm is available through its website, www.holzerlaw.com and upon request from the firm. Holzer Holzer & Fistel, LLC has paid for the dissemination of this promotional communication, and Michael I. Fistel, Jr. is the attorney responsible for its content.

NTS Realty Holdings, LP Proposed Buyout Investigated by the Securities Attorneys at The Briscoe Law Firm and Powers Taylor, LLP

Former United States Securities and Exchange Commission attorney Willie Briscoe and the securities litigation firm of Powers Taylor, LLP are investigating potential legal claims against the Board of Directors of NTS Realty Holdings, LP (“NTS”) (NYSE MKT: NLP) related to a proposed buyout by its founder and Chairman and Chief Executive Officer for shareholders. Under the terms of the proposal, NTS’s founder and Chairman, Mr. J.D. Nichols, and its Chief Executive Officer, Mr. Brian F. Lavin, would acquire all of the public limited partnership interests in NTS for $5.25 per share in cash. Currently, Messrs. Nichols and Lavin beneficially own 62% of NTS’s limited partnership interest representing about 59% of its voting power.

If you are an affected investor, and you want to learn more about the lawsuit or join the action, contact Patrick Powers at Powers Taylor, LLP, toll free (877) 728-9607, via e-mail at patrick@powerstaylor.com, or Willie Briscoe at The Briscoe Law Firm, PLLC, (214) 706-9314, or via email at WBriscoe@TheBriscoeLawFirm.com. There is no cost or fee to you.

According to shareholder rights attorney Willie Briscoe, “The investigation relates to the fairness of the proposed transaction to NTS’s shareholders and whether the Board of Directors is adequately shopping the company in order to obtain the best possible price for the shareholders. In addition, the firms are actively investigating possible breaches of fiduciary duty and other violations of state law by the Board of Directors of NTS in connection with the potential approval of this transaction, and whether NTS’s Board of Directors is acting in the shareholders’ best interests.”

The Briscoe Law Firm, PLLC is a full service business litigation and shareholder rights advocacy firm with more than 20 years of experience in complex litigation and transactional matters.

Powers Taylor, LLP is a boutique litigation law firm that handles a variety of complex business litigation matters, including claims of investor and stockholder fraud, shareholder oppression, shareholder derivative suits, and security class actions.

Law Firm of Wohl & Fruchter Commences Investigation into Proposed Acquisition of NTS Realty Holdings Limited Partnership by Chairman and CEO

The law firm of Wohl & Fruchter LLP has commenced an investigation into a proposal to acquire all of the outstanding publicly-held limited partnership interests of NTS Realty Holdings Limited Partnership (NYSE: NLP) submitted by NLP’s founder and Chairman, J.D. Nichols, and CEO, Brian Lavin.

On August 31, 2012, the board of directors of NLP’s managing general partner announced that it had received a non-binding proposal from Messrs. Nichols and Lavin to acquire all of the publicly-held limited partnership interests of the Company for $5.25 per unit in cash. As of June 30, 2012, Mr. Nichols beneficially owned approximately 61.7% of the outstanding limited partnership units of NLP.

Wohl & Fruchter’s investigation concerns the fairness of the buyout proposal, and the adequacy of the procedures adopted by NLP in response to the proposal.

Additional information is available at http://www.wohlfruchter.com/cases/nlp.

Persons with relevant information, and NLP unitholders with questions about this investigation, are invited to contact our Firm at 866.582.8140, or the attorney below.

About Wohl & Fruchter

Wohl & Fruchter LLP represents plaintiffs in litigation arising from fraud and other fiduciary breaches by corporate managers, as well as other complex litigation matters. Please visit our website, www.wohlfruchter.com, to learn more about our Firm, or contact one of our partners.

This release may be deemed to constitute attorney advertising.

Cell Therapeutics, Inc. (CTIC) Appoints Former Managing Director

Cell Therapeutics, Inc. (CTI) Appoints Former Managing Director, Head of West Coast Biotechnology for Oppenheimer/CIBC Matthew J. Plunkett Executive Vice President, Corporate Development
Experienced investment banker to lead strategic business initiatives

SEATTLE, Sept. 4, 2012 /PRNewswire/ — Cell Therapeutics, Inc. (CTI) (NASDAQ and MTA: CTIC), a company focused on translating science into novel cancer therapies, today appointed former Managing Director and Head of West Coast Biotechnology for Oppenheimer & Co. and its U.S. predecessor, CIBC World Markets, Matthew J. Plunkett, Ph.D., as CTI’s Executive Vice President, Corporate Development. Dr. Plunkett will lead CTI’s partnering strategy including development collaborations, licensing agreements, and strategic alliances.

Dr. Plunkett has more than 15 years’ experience in the biopharmaceutical industry. This includes 9 years at Oppenheimer & Co. and CIBC World Markets. Dr. Plunkett advised on more than 70 completed transactions companies in the U.S., Europe and Australia, including more than $4 billion in equity and equity-linked transactions and $1 billion in merger, acquisition and other financial advisory transactions.

Most recently, Dr. Plunkett was Chief Financial Officer at the California Institute for Regenerative Medicine, a $3 billion fund for California stem cell research. He also served as Vice President and Chief Financial Officer at iPierian, a privately-held development-stage biotechnology company. He began his scientific career at Sunesis Pharmaceuticals and Axys Advanced Technologies. Dr. Plunkett received a doctorate in Organic Chemistry from the University of California, Berkeley, and a bachelor of science in Chemistry from Harvey Mudd College, Claremont, California.

“Matt has a wealth of experience in financing, mergers, acquisitions and technology/market assessments,” said James A. Bianco, M.D., President & CEO of CTI.

“CTI is one of a select few companies that both have the opportunity of a product approved in Europe, and drug candidates with attractive commercial potential for different blood-related cancers,” Dr. Plunkett said. “It is all the more impressive that CTI has been able to establish this pipeline during a time of unprecedented challenges for the biotech industry. I look forward to contributing to CTI’s success with value-creating transactions.”

About Cell Therapeutics, Inc.

Headquartered in Seattle, CTI is a biopharmaceutical company committed to developing an integrated portfolio of oncology products aimed at making cancer more treatable. For additional information, please visit www.CellTherapeutics.com.

Sign up for email alerts and get RSS feeds at our Web site, http://www.CellTherapeutics.com/investors_alert

Media Contact:

Dan Eramian
T: 206.272.4343
C: 206.854.1200
E: deramian@ctiseattle.com
www.CellTherapeutics.com/press_room

Investors Contact:

Ed Bell
T: 206.282.7100
F: 206.272.4434
E: invest@ctiseattle.com
www.CellTherapeutics.com/investors

SOURCE Cell Therapeutics, Inc.

Seven Arts Entertainment (SAPX) Confirms 1-for-70 Reverse Stock Split

Seven Arts Entertainment Confirms 1-for-70 Reverse Stock Split Effective at the Opening of the Markets on Tuesday, September 4, 2012 and Announces Dividend

LOS ANGELES, CA — (Marketwire) — 09/04/12 — Seven Arts Entertainment Inc. (NASDAQ: SAPX) (“Seven Arts” or the “Company”) confirmed today its 1-for-70 reverse split of its common stock that was effective immediately after the close of the markets on Friday. The new CUSIP number for the Company’s common stock is 81783N 201.

Seven Arts also announced that, subject to appropriate and required regulatory filings and approvals, it has declared a warrant dividend to those persons beneficially owning its common stock as of the close of the markets on August 31, 2012. For every ten pre-reverse split shares of common stock held as of such date and time, the holders thereof will be entitled to receive one warrant as a dividend. Until its expiry date, each warrant, once distributed following such approvals, will be exercisable for the purchase of one share of the Company’s post-reverse split common stock at a price equivalent to today’s post-reverse split closing bid price. The warrants will expire on the earlier of (i) the date that the holder disposes of the common stock in respect of which the warrant dividend was declared, if such disposition occurs on or before the close of the markets on October 31, 2012, or (ii) 5:00 p.m., PST, on January 31, 2013. Seven Arts does not expect that a secondary market will develop for such warrants.

The Company remains concerned with the heavy volume of reported trading in its common stock and believes it is primarily based on trading programs and other trading strategies, some of which may be improper. Accordingly, the Company’s transfer agent will verify certain records at DTC and at other sources to ensure that this dividend is only received by persons who owned common stock at the close of the markets on August 31, 2012. The Company believes that the dividend of one warrant per share may provide certain economic value to existing stockholders during and immediately following the reverse split process and thereafter until such time as the fundamental growth and profits of Seven Arts are recognized by the public markets. Management remains optimistic regarding the results of operations for the fiscal year ended June 30, 2012, which should be reported by the end of September, 2012, and with the prospects of its motion picture and music businesses.

About Seven Arts Entertainment Inc.:
Seven Arts Entertainment Inc. is the successor to Seven Arts Pictures Plc, which was founded in 2002 as an independent motion picture production and distribution company engaged in the development, acquisition, financing, production and licensing of theatrical motion pictures for exhibition in domestic (i.e., the United States and Canada) and foreign theatrical markets, and for subsequent worldwide release in other forms of media, including home video and pay and free television.

Cautionary Information Regarding Forward-Looking Statements.
Forward-looking statements contained in this press release are made under the Safe Harbor Provision of the Private Securities Litigation Reform Act of 1995. Any such statements are subject to risks and uncertainties that could cause actual results to differ materially from the anticipated. The information contained in this release is as of September 4, 2012. Seven Arts assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments.

Contact:

Seven Arts Entertainment Inc.
Peter Hoffman
323-372-3080
phoffman@7artspictures.com